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INTRODUCITON 
 
 
 Stroke is a world wide health problem. It makes an important 
contribution to morbidity mortality and disability in developed as well as 
developing countries, like India.  
 Cerebral thrombosis is the most frequent form of stroke encountered in 
clinical studies, followed by intracerebral hemorrhage. Subarachnoid 
hemorrhage and cerebral embolism come next as regards to both mortality and 
morbidity. 
 After rupture of an atherosclerotic plaque in the cerebral artery there is 
platelet adhesion activation and aggregation leading to the formation of a 
thrombus. Higher the number of reactive platelets higher are the chances for 
cerebral ischemic strokes. 
 Bancroft et al (2000) reported that platelet volume is a marker and 
possibly a determinant of platelet function in that, larger platelets are more 
reactive than normal sized platelets.  
 Philip Bath et al (2004) observed an association between increased mean 
platelet volume and increased occurrence of stroke.  
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REVIEW OF LITERATURE 
 
 The role of platelets in acute myocardial infarction has been appreciated 
for several decades. Yet the last 5-10 years have seen a dramatic increase in the 
understanding, development, clinical evaluation and therapeutic application of 
platelet inhibitor therapy. 
 Platelets play an essential role in haemostasis, thrombosis and 
coagulation of blood. These tiny cells previously described as “sponges” 
(Adelson et al, 1961) are known to engage in a complex repertoire of 
biochemical and molecular activities designed to prevent haemorrhage. 
 
PLATELET STRUCTURAL AND FUNCTIONAL ANATOMY 
Light Microscopy  
 On Wright-Glemsa stained blood smears, platelets appear as small 
anucleate, ovoid  or round cells, with a pale grayish blue cytoplasm that 
contains homogeneously distributed purple-red granules. 
Dimensions  
 The volumes of circulating platelets from a single individual are 
heterogeneous and exhibit a lognormal size distribution; and the platelet volume 
in a single individual (mean platelet volume, MPV) varies from 7 to 9 
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femtolitres. (Paulus, 1975; Martin et al, 1982; Stenberg and Levin, 1989; 
Corash, 1977). 
Electron Microscopy and Subcellular Organelles 
By scanning electron microscopy, circulating blood platelets appear as 
flat discs, with smooth contours and rare spiny filopodia. Scanning electron 
microscopy also reveals random openings of a channel system, the surface 
connected canalicular system, which invaginates throughout the platelet  and is 
the conduit by which granule contents exocytose after stimulation.  Although 
the platelet is anucleate, transmission electron microscopy reveals a cytoplasm 
packed with a number of different organelles essential to the maintenance of 
normal haemostasis. 
Glycocalyx  
 Structure : A glycocalyx, 15 to 20 nm thick, is visualized by 
transmission electron microscopy and contains glycoproteins, glycolipids, 
mucopolysaccharides, and adsorbed plasma proteins. 
 Function : The glycocalyx has a net negative surface charge due to 
sialic acid residues on the proteins and lipids; the charge is thought to minimize 
attachment of circulating platelets to each other (Coller, 1984). This structure is 
rich in carbohydrate moieties of membrane-associated glycoproteins, which 
serve as receptors to mediate transfer of signals by stimulatory agents.  The 
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glycocalyx interacts with platelet activators to facilitate platelet adhesion and 
aggregation. 
Plasma Membrane 
 Structure : The platelet plasma membrane is a typical trilaminar 
membrane with glycoproteins, glycolipids, and cholesterol embedded in a 
phospholipid bilayer. 
 Function :  The plasma membrane contains sodium and calcium ATPase 
pumps, which are important for maintaining ionic homeostasis. It has a 
specialized role in providing a surface for the acceleration of blood coagulation, 
in that a specific platelet coagulant protein, platelet factor 3, resides in this 
lipoprotein-rich unit membrane. 
Surface-connected Canalicular System 
 Structure :  The surface-connected canalicular system, also called the 
open canalicular system, weaves throughout the cell cytoplasm in a tortuous 
fashion. 
 Function : The functions of the surface connected canalicular system 
are to provide a route of entry and egress for molecules, an internal reservoir of 
membrane to facilitate platelet spreading and filopodia formation after adhesion 
and a storage reservoir for membrane glycoproteins that increase on the platelet 
surface after activation. 
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Dense Tubular system  
 Structure :  Unlike the surface-connected canalicular system, the dense 
tubular system is a closed-channel system consisting of narrow, membrane 
limited tubules, approximately 400 to 600 A in diameter. It is, infact, residual 
smooth endoplasmic reticulum from the megakaryocyte. 
 Function :  This channel system is involved in the regulation of 
intracellular calcium transport because it has been reported to selectively bind, 
sequester, and release divalent cations after activation.  The dense tubular 
system is also the site of prostaglandin synthesis in platelets.   
Cytoskeleton  
 General Structure : The platelet cytoskeleton contains 30 to 50% of 
total platelet protein and is made up of three major structural components : an 
actin microfilament network present throughout the cytoplasm, a micro tubule 
coil localized at the platelet periphery and a membrane skeleton comprising a 
network of short actin filaments that underlies the inner surface of the plasma 
membrane.  Although they are distinct structures, interconnections between 
these elements are present. 
Structure and Function of Specific Cytoskeletal Elements 
 Actin Microfilaments : Twenty to thirty percent of total platelet protein 
is made up of actin (Pollard, 1990).  Actin exists in two forms, G-actin (actin 
monomers) and F-actin (polymerized actin).  In the unstimulated platelet, 30 to 
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40% of actin is polymerized into filaments;  the balance of actin monomers are 
prevented from polymerizing by proteins such as profilin or thymosin B4 that 
sequester monomeric actin, or by proteins that cap filaments in the intact cell, 
such as gelsolin. 
 Upon platelet activation, the proportion of filamentous actin rapidly 
increases to 60-70%.  Actin monomers polymerize onto filaments at platelet 
peripheries and bundles of new filaments form to fill developing filopodia. 
 Microtubules :  A circumferential microtubule band that supports the 
discoid form of the platelet is made up of two nonidentical subunit proteins ( 
alpha and Beta tubulin) associated with microtubule associated proteins  
(MAPs).  The 25 nm diameter microtubule coil lies adjacent to, but does not 
touch, the plasma membrane. 
 Microtubules are present primarily in their polymerized form in 
unstimulated platelets. Platelet activation results in microtubule disassembly, 
then reassembly; such alterations in the marginal microtubule bundle result in 
platelet shape changes. 
 Membrane Skeleton :  The short actin filaments of the membrane 
skeleton, which underlie the inner surface of the plasma membrane, together 
with the microtubule coil, are thought to help stabilize the platelet discoid 
shape. 
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 Two major platelet membrane glycoproteins, GP IIb-IIIa and GP Ib-IX 
are associated with the membrane skeleton. 
Granules 
 Platelets contain four distinct populations of granules: alpha granules, 
dense bodies, lysosomes, and microperoxisomes.  After platelet stimulation by 
agonists, granules fuse with channels of the surface-connected canalicular 
system and extrude their contents (White, 1974).  Internal contraction is 
required for this extrusion and ultimate discharge into the surrounding medium. 
α  - Granules : 
 Structure :  α Granules are the predominant granule type in the platelet.  
The α granule has been subdivided morphologically into three distinct zones by 
electron microscopy : an electron- dense nucleoid that occupies the bulk of the 
granule, a peripheral zone of lower electron density that lies adjacent to the 
granule membrane and 1 to 6 tubular structures that reside in the electron lucent 
peripheral zone. 
 Content : B-thromboglobulin and platelet factor 4 have been localized 
to the dense nucleoid. Von Willebrand factor is present in the tubular structures 
of the granule peripheral zone.  Thrombospondin, and fibrinogen are present in 
the granular matrix.  Other proteins present in α granules include albumin, 
immunoglobin G (IgG), fibronectin, platelet derived growth factor, GPIIb-IIIa,  
Beta amyloid protein precursor, factor V, multimerin, a factor V/Va binding 
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protein, transforming growth factor β1 and a plasminogen activator similar to 
tissue plasminogen activator. 
 Proteins present on the α – granule membrane include P-selectin, GP IIb 
/ IIIa, granule membrane protein – 33 (GMP-33), CD9, platelet – endothelial 
cell adhesion molecule 1 (PECAM-1) and osteonectin. 
 Dense Bodies : 
 Structure :  Ultrastructurally, dense granules have a bull’s eye 
appearance.  They are the most electron-dense organelles in platelets. 
 Content :  The principal constituents of dense granules are a 
nonmetabolic pool of adenine nucleotides (adenosine triphosphate and 
diphosphate, ATP and ADP), PPi, calcium and magnesium and serotonin (5-
hydroytryptamine). In addition, dense bodies contain guanosine triphosphate 
and diphosphate (GTP and GDP). The dense granule membrane contains P – 
selectin and granulophysin. 
 Lysosomes : 
 Structure :  Lysosomes are small vesicles of approximately 175 to 200 
nm.   
 Content :  Lysosomes are the only platelet granules that contain acid 
hydrolases.  Platelet lysosomes contain a large variety of enzymes, including β 
hexosaminidase and β glycerophosphatase.  Lysosomal membrane glycoprotein 
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(LIMP-CD63) and lysosomal associated membrane proteins 1 and 2 (LAMP-1 
and LAMP-2) become expressed on the plasma membrane after activation. 
 Microperoxisomes : 
 Structure :  Microperoxisomes are small (90-nm) granules that are 
relatively few in number in platelets and can be demonstrated only 
cytochemically. 
 Content :  They are reactive with alkaline diaminobenzidine medium.  
The enzyme responsible for the cytochemical peroxidase activity in 
microperoxisomes is catalase. 
Coated Vesicles : 
 Structure :  Coated vesicles are 70 to 90 nm organelles  
 Content :  The polyhedral coat on the surface of these vesicles is 
composed of clathrin.  Coated pits and vesicles transfer plasma components to 
platelet granules (Behnke, 1989). 
Mitochondria : 
 Structure :  Mitochondria in platelets are similar, with the exception of 
smaller size to those in other cell types. There are approximately seven per 
human platelet.  
 Content :  Mitochondria are the site of activity for all components of the 
respiratory chain and for almost all enzymes in the citric acid cycle. 
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Glycogen  
 Platelets contain small particles of glycogen or masses of closely 
associated glycogen particles; these play an essential role in platelet 
metabolism. 
 
(Diagram of a human platelet displaying components visible by electron 
microscopy and cytochemistry) 
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PLATELET PHYSIOLOGY 
Platelet Lipids and Proteins 
Membrane Lipids 
 Phospholipids constitute 80% of the total platelet lipid, although smaller 
amounts of neutral lipids and glycolipids are also present. The five major 
phospholipids identified in human platelets are phosphatidylcholine, 
phosphatidylethanolamine, sphingomyelin, phosphatidylserine and 
phosphatidylinositol.  Almost all platelet fatty acids are esterified in 
phospholipids, leaving only trace amounts of free fatty acids.  Arachidonic acid, 
the precursor of prostaglandins and thromboxanes, is enriched in these 
phospholipids and the metabolism of arachidonic acid is critical for normal 
platelet function (Marcus, 1976). 
 Neutral lipids make up approximately 28% of total platelet lipids, the 
predominant neutral lipid being cholesterol. 
Membrane Glycoproteins : 
 Platelet membrane glycoproteins mediate a wide number of adhesive 
cellular interactions.  These glycoproteins function as receptors that can receive 
signals from outside the platelet, facilitating cell – cell interactions; binding of 
specific ligands to these receptors results in distinct platelet responses to the 
external environment. 
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Glycoprotein  IIb / IIIa : Glycoprotein IIb-IIIa is the principal receptor 
on the platelet plasma membrane (Philips et al, 1988).  It is a member of the 
integrin family of proteins. A Ca2+ dependent conformational change in GP 
IIb-IIIa after platelet agonist indued stimulation facilitates strong binding to 
fibrinogen and VWF resulting in cross linking of GP IIb-IIIa molecules on 
adjacent platelets and platelet aggregation. 
 Glycoprotein Ib-IX : Glycoprotein Ib mediates the interaction of 
platelets with VWF. GP Ib also functions as a binding site for thrombin. GP Ib 
is present on platelet surfaces in a 1:1 ratio with GP IX.   
 Other membrane Glycoproteins :  Membrane glycoproteins GPIa-IIa, 
GPIc – IIa, mediate platelet adhesion to collagen, fibronectin, laminin and 
vitronectin.  GP V forms a noncovalent complex with GP Ib – IX in the platelet 
membrane. PECAM-1 binds to heparin like molecules.  GPIV is a receptor for 
thrombospondin.  GP IV is also reported to bind collagen. 
Other Platelet Proteins : Other proteins presented in the platelet are platelet 
factor 4, β thromboglobulin, thrombospondin, platelet derived growth factor, 
fibronectin.   
 Platelet Factor 4:  PF4 binds heparin with high affinity and neutralizes 
its anticoagulant activity.  It exhibits a variety of activities, including the 
potentiation of platelet aggregation. 
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PLATELET BIOCHEMISTRY 
 The platelet has minimal ability to synthesize protein because it contains 
only low levels of RNA and lacks a nucleus.  In terms of dry weight, the 
platelet is composed of approximately 60% protein, 15% lipid and 8% 
carbohydrate.  Platelet minerals include magnesium, calcium potassium and 
zinc.  Platelets contain substantial amounts of vitamin B12, folic acid, and 
ascorbic acid. 
Platelet Energy Metabolism 
 There are several similarities between the energy metabolism of the 
platelet and that of skeletal muscle.  Both involve active glycolysis and the 
synthesis and use of large amounts of glycogen and in both, the major mediator 
of intracellular energy use in an actomyosin-like adenosine triphosphatase.  The 
platelet, like muscle, is metabolically adapted to expend large amounts of 
energy rapidly during aggregation, the release reaction, and clot retraction. 
 The major energy source for the platelet is glucose, which is rapidly 
taken up from the plasma. 
 A simplified scheme of platelet energy metabolism is shown in the 
figure below. Platelet energy is derived from the metabolism of glucose and to a 
lesser extent from the metabolism of fatty acids. Energy is provided in 
approximately equal amounts by glycolysis and the citric acid cycle. The 
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platelet energy reserve is provided by the metabolic pool of platelet nucleotides 
that is in a state of continuous turnover.  
 
(Platelet energy metabolism) 
Nucleotide Metabolism  
 Adenine nucleotides constitute 90% of free platelet nucleotides and are 
partitioned into at least two different pools, which undergo minimal 
interchange. The metabolic or cytoplasmic pool makes up 40% of total adenine 
nucleotides; it is used for the maintenance of various energy-consuming cell 
functions and is retained during platelet release. 
 The storage pool, which is present in the dense bodies, contains 
approximately two-thirds of the total platelet nucleotides, mainly in the form of 
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ADP and ATP.  It is metabolically inactive, does not rapidly incorporate 
exogenous adenine or phosphate, and equilibrates slowly with the metabolic 
pool.  Nucleotides in this pool are extruded from the platelet during the release 
reaction and cannot be replenished after release. ATP hydrolysis is required for 
conversion of G actin to F-actin. The ATP that is broken down to provide 
energy for the release reaction is not rephosphorylated, but rather is irreversibly 
degraded to hypoxanthine which diffuses out of the cell. Platelets also contain 
guanine nucleotides and uracil and cytosine pyrimidines. 
Arachidonate Metabolism  
 Arachidonic acid is released from platelet membrane phospholipids  
after stimulation by numerous agonists through the enzymatic action of 
phospholipase A2 or the combination of phospholipase C and diglyceride 
lipase.  After release, arachidonic acid can be acted on by either lipoxygenase, 
which results in the production of peroxy and hydroxy fatty acids, or by 
cyclooxygenase, which ultimately results in production of thromboxanes and 
prostaglandins. 
Platelet “Coagulation” Factors  
 Numerous platelet proteins interact with plasma coagulation proteins 
although the mechanisms by which platelet membrane component become 
reorganized and capable of functioning as a catalytic surface for plasma 
proteins are not known. 
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 Several plasma coagulation factors are associated with platelets, 
including von Willebrand factor, coagulation inhibitors, and factor XIII. 
 Various substances associated with or derived from the platelet have 
been designated platelet factors 1 to 10 and denoted by Arabic numerals. The 
most important of these are PF4 and PF3. 
Platelet Factor 3 
 PF3 is required in at least two steps in the process of blood coagulation, 
namely the interaction between factors IXa and VIIIa, which results in the 
activation of factor X, as well as the interaction between factor Xa and factor 
Va which leads to the formation of prothrombinase.  These coagulation 
reactions are greatly accelerated on the platelet surface. 
PLATELET COUNT 
 The normal platelet count varies between  
1,50,000 – 3,50,000 / mm3 
ORIGIN OF PLATELETS FROM MEGAKARYOCYTES  
 The megakaryocyte is a large hematopoeitic cell, the cytoplasm of which 
fragments to form circulating blood platelets. The histogenesis of platelets from 
megakaryocytes was first described by James Wright in 1910.  The 
megakaryocytes are sessile polyploid cells which inturn descend from diploid 
pluripotent hematopoeitic stem cells of marrow. The megakaryocytes are 
imprisoned within the sub endothelial layer of marrow sinuses by their very 
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girth and volume (average 5000 femtolitres, Zhang YJ, 1991).  In these marrow 
niches, mononuclear progenitors undergo diploid doublings by the unique 
process of endomitosis.  Subsequently the polypoid megakaryocytes 
accumulate a bulky compartmentalized cytoplasmic mass with large volumes 
that at end stage maturation disintegrates abruptly to yield between 1000 and 
8000 platelets having a volume of 7-9 femto litres each (Martin et al, 1982; 
Stenberg and Levin, 1989; Corash, 1989). Megakaryocytes are suicidal 
microorgans whose mission is to proliferate and then fragment their cytoplasm 
on demand to maintain blood platelets at relatively steady levels of about 
1,50,000 – 3,50,000 / mm3. 
 Maintenance of platelet counts within this range represents a surplus of 
over 10 times that necessary to ensure routine haemostasis but provides a 
precautionary reserve for times of excess platelet loss or consumption. 
PLATELET LIFE SPAN, TURN OVER & REMOVAL  
 Platelet life span, based on the time required to clear labeled platelets 
from circulation, has been estimated to be 8-12 days in humans. The sites for 
platelet removal appear to be the spleen, the liver & bone marrow.  
Degranulation and loss of density and platelet constituents has not been shown 
to decrease platelet life span indicating that the number of haemostatic 
interactions may not be a key component. 
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PLATELET ADHESION, ACTIVATION & AGGREGATION  
 The anti thrombotic properties of intact vascular endothelium include 
potent platelet inhibitors. These inhibitors include PGI2, NO & CO which are 
labile molecules that are released by endothelial cells and act locally as 
autocoids and ADPase, an ectonucleotidase of endothelial membranes that 
breaks down platelet activating ADP. 
Adhesion  
 On vascular intimal injury, the antiplatelet properties of endothelium are 
diminished locally, while previously cryptic, thrombogenic subendothelial 
substances eg. collagen become exposed to flowing blood. Circulating platelets 
recognize sites of vascular disruption and undergo the process of adhesion to 
the site of injury.  Platelet adhesion is mediated by von willebrand factor which 
is present in the extracellular matrix of sub endothelial vessel wall.  The 
receptor of von willebrand factor on the platelet surface is localized in 
membrane glyco protein (Gp) Ib, part of the platelet membrane Gp Ib / IX-V 
complex. Platelet adhesion is also facilitated by direct binding to subendothelial 
collagen by means of specific platelet membrane collagen receptors. 
Activation 
 Adherent platelets then become activated.  The platelet activation 
process results from the combined actions of several agonists that bind to their 
respective membrane receptors on adherent platelets and transmit platelet 
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activating intracellular signals.  These platelet stimuli include humoral 
mediators in plasma (epinephrine, thrombin), mediator released from activated 
cells, (ADP serotonin), vessels wall extracellular matrix constituents that come 
in contact with adherent platelets (eg. collagen, von willebrand factor).  
Activated platelets then undergo release reaction during which they secrete 
prepackaged constituents of their cytoplasmic granules.  The constituents 
released from dense granules are ADP, ATP serotonin.  The constituents 
released from alpha granules are soluble adhesive proteins (fibrinogen, von 
willebrand factor, thrombospondin, fibronectin), growth factors (PDGF, TGF α, 
TGF β) procoagulants (platelet factor 4, Factor V). Simultaneously, activated 
platelets synthesize denovo and release the potent platelet activator and 
vasoconstrictor  thromboxane A2 (TX A2) 
Aggregation  
 The products of the platelet release reaction, including secreted granule 
constituents and TXA2 mediate aggregation.  During platelet aggregation 
(platelet – platelet interaction), additional platelets are recruited from 
circulation to the site of vascular injury leading to the formation of an occlusive 
platelet thrombus. At lower shear levels (eg. in venous circulation), the 
molecular glue that mediates aggregation is fibrinogen, which can be derived 
either from plasma or from the alpha granule releasate of activated platelets.  At 
higher shear level (eg. in arteries) von willebrand factor can substitute for 
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fibrinogen as the ligand of aggregation.  Fibrinogen or von willebrand factor 
binds to the specific platelet membrane receptor that are located in the Gp IIb / 
IIIa integrin complex and mediates aggregation and finally the platelet plug is 
formed. The platelet plug is anchored and stabilized by the fibrin mesh that 
develops simultaneously as the product of the coagulation cascade. 
PATHOGENESIS OF ACUTE STROKE  
 Ischemic stroke result from blockage of a cerebral artery by cerebral 
thrombosis occurring in an area of atherosclerotic plaque rupture. During the 
natural evolution of atherosclerotic plaques, especially those that are lipid 
laden, an abrupt and catastrophic chain of events may occur starting with a 
plaque rupture. After plaque rupture there is exposure of substances that 
promote platelet activation and aggregation, thrombin generation and ultimately 
thrombus formation. The resultant thrombus that is formed interrupts blood 
flow and leads to an imbalance between oxygen supply and demand and if this 
imbalance is severe and persistent, it leads to cerebral necrosis.   
PLATELET VOLUME AND CEREBRO VASCULAR DISEASE 
 As the initial step in the pathogenesis of acute stroke is plaque erosion or 
rupture followed by platelet adhesion, activation and aggregation followed by 
thrombus formation, platelets with more activity will predispose to the 
occurrence of stroke. Mean platelet volume (MPV) correlates with platelet 
function and activation, whether measured as aggregation, thromboxane 
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synthesis, beta thromboglobulin release, procoagulant function or adhesion 
molecule expression (Bath et al, 1996). 
 Increased platelet reactivity as well as shortened bleeding time are 
associated with increased platelet volume (Milner and Martin, 1985; 
Trowbridge and Martin, 1987). Large platelets are metabolically and 
enzymatically more active than small platelets as assessed by in vitro 
aggregometry (Corash et al 1977) and they have a higher thrombotic potential 
(Karpatkin 1972). They also express higher levels of procoagulatory surface 
proteins such as P – selectin (Mathur et al, 2001) and glycoprotein III a 
(Pathansali et al, 2001). 
 Large platelets are denser and they produce more thromboxane A2 per 
unit volume of platelet cytoplasm and decrease bleeding time more than control 
platelets. Larger platelets aggregate more rapidly upon collagen challenge, 
release more serotonin and other granule contents and express more receptors 
per unit area (Pizzuli et al, 1998).  
Platelet morphology and physiology are determined during or even 
before fragmentation of their precursor cell, the megakaryocyte (Rabellino et al 
1981).  Although the mechanism is still unclear, megakaryocyte ploidy seems 
to correlate closely with platelet volume (Hoffman and Long 1995).  Although 
ploidy and platelet volume are independent variables, alterations in both 
parameters usually occur in tandem (Trowbridge and Martin, 1987).  Certain 
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cytokines such as Interleukin-3, thrombopoetin and in particular interleukin 6 
(IL-6) seem to have a major influence on megakaryocyte ploidy leading to the 
production of larger and more reactive platelets (Debilli et al 1993; Brown et al 
1997). Recently a frequent G/C polymorphism in the promoter region of IL-6 at 
nucleotide position (-174) has been shown to influence IL-6 serum levels 
(Fishman et al 1998).  In individuals carrying the common G allele, higher IL-6 
levels have been found compared to the levels in carriers of the C allele 
(Fishman et al 1998). 
 Large platelets are not necessarily young platelets (Martin et al, 1983) 
and there is now no convincing evidence that platelets appreciably change 
volume or density as they circulate (Penington, 1976).  
Greisenegger et al (2004), Philip Bath et al (2004) and O’ Malley et al 
(1994) reported an association between mean platelet volume and the 
occurrence of acute strokes.  
Platelet volume and prognosis following acute stroke  
 Philip Bath et al (2004) concluded that MPV is an independent risk 
factor for stroke and measurement of MPV may provide useful prognostic 
information for clinicians managing patients with cerebro vascular disease.  
 Greisenegger et al (2004) observed that an elevated MPV is associated 
with a worse outcome for acute ischemic stroke.  
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AGE, GENDER AND MPV 
Funiak et al (1994) observed increased MPV in patients of advanced age. 
In contrast Bancroft et al (2000) observed decreased MPV with advanced age. 
No difference between genders were detected by the latter author.  
MPV AND SMOKING 
Smokers were found to have an increased MPV (Tschope et al, 1989; 
Kario et al, 1992). 
MPV AND OTHER DISEASES 
An increased MPV was observed in diabetics compared to non diabetics 
by Sharpe et al (1993). 
Although Osuna et al (1998) observed a higher MPV in patients with 
systemic hypertension, Bath et al (1996) observed no such effect. 
Ford et al (1998) observed that patients with hyperthyroidism had 
increased MPV. 
Bansal et al (2002) noted that MPV was increased in patients with 
chronic obstructive pulmonary disease and this could possibly contribute to an 
increased incidence of pulmonary embolism in these patients.  
In chronic liver disease, MPV and platelet count have been reported to 
be low (Jorgensen et al, 1984). 
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MPV AND DRUGS 
Aspirin has no effect on MPV (Pizulli et al, 1998). Recently, invitro data 
on the therapeutic effects of losartan, an angiotensin II receptor antagonist or 
Doxasosin, an alpha 1 adrenoceptor antagonist, on platelet volume have been 
reported (Jagroop and Mikhailidis 2001). These observation have not been 
confirmed in vivo (Jagroop and Mikhailidis 2000).  
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AIM AND OBJECTIES  
 
 
1) To assess the mean platelet volume in the local population presenting 
with ischemic stroke and compare the same with patients presenting with 
hemorrhagic stroke.  
 
2) To observe if any correlation between mean platelet volume and severity  
 of stroke at admission and in hospital out come over 1 to 2 weeks.   
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MATERIALS AND METHODS 
 
Setting    : Dept of Medicine 
     Govt. Rajaji Hospital and  
     Madurai Medical College, Madurai 
Collaborating Department :  Laboratory Services  
     Apollo Speciality Hospital, Madurai  
Design of Study   : Cross Sectional Study. 
Period of Study   :  July 2006 – June 2007 
Sample Size    : 50 Patients and 50 controls  
Ethics Committee approval : The present project was approved by the  
   ethics committee. 
Inclusion Criteria: 
 Patients presenting with stroke admitted to the medical wards of 
Government Rajaji Hospital.  
Exclusion Criteria: 
1. Septicemia. 
2. Hematological disorders like idiopathic thrombocytopnoea, 
thrombocytosis, acute leukaemia, chronic leukaemia     
3. Presence of blood loss 
4. Hyperthyroidism  
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5. Chronic liver disease 
6. Chronic obstructive pulmonary disease 
7. Chronic renal failure on erythropoietin therapy. 
8. Known malignancies. 
Controls : 
 Control population comprised of age and gender matched subjects 
without stroke and asymptomatic.  
Consent : 
 Informed consent was obtained from all patients who participated in the 
study or their relatives of patients who could not sign the consent.   
Materials : 
 A fifty patients conforming to inclusion and exclusion criteria were 
analysed and compared with fifty age and gender matched controls.  
Definitions used for the study:  
1. Stroke: was defined by an abrupt onset of a neurologic deficit that was 
attributable to a focal vascular cause. Thus the definition of stroke was 
essentially clinical and laboratory studies including brain imaging were used to 
support the diagnosis.   
2.  Systemic hypertension: 
 A subject was considered to have systemic hypertension if he was 
already diagnosed to have systemic hypertension (according to JNC VII report) 
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and with or without anti hypertensive medication or if there was evidence of 
target organ damage attributed to hypertension even if there was no past history 
of hypertension.  
3. Diabetes Mellitus: 
 A subject was considered to have diabetes mellitus if he/she was already 
diagnosed to have diabetes mellitus or during the hospital stay was found to 
have a  
 fasting plasma glucose of > 126mg/dl  
   Or 
 2 Hour postprandial plasma glucose > 200mg/dl 
   Or 
 Symptoms of diabetes mellitus plus random blood sugar > 200 mg /dl 
(according to ADA criteria) 
4. Recent Acute Myocardial Infarction: 
 A patient was considered to have acute myocardial infarction if he / she 
gave a definite clinical history suggestive of acute myocardial infarction and 
had ECG changes suggestive of acute myocardial infarction within two weeks 
duration.  
5. Atrial Fibrillation:  defined by characteristic pattern of disogransied atrial 
activity without discreate p waves on the surface ECG.  
6. Body mass index: = weight in kg / height in m2   
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7. Smoking:  A subject was considered to be a smoker if he / she gave a history 
of tobacco smoking within the past five years. Person who had quit smoking 
completely before five years were not considered as smokers. 
8. Alcoholic: A subject was considered to be an alcoholic if he / she gave a 
history of increased alcohol intake within past five years. Persons who had quit 
alcohol completely before 5 years were not considered as alcoholic.   
9. Physical activity should be moderate or vigorous and add up to at least 30 
minutes a day  
  Moderate physical activities include  
٭ Walking briskly ( about 3 ½ miles per hour)  
٭ Hiking  
٭ Gardening /yard work  
٭ Dancing  
٭ Golf ( Walking and carrying clubs)  
٭ Bicycling ( less than 10 miles per hour )  
٭ Weight training ( general light workout)  
Vigorous physical activities include  
٭ Running / jogging ( 5 miles per hour) 
٭ Bicycling ( more than 10 miles per hour )  
٭ Swimming ( freestyle laps)  
٭ Aerobics 
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٭ Walking very fast (4 ½ miles per hour)  
٭ Heavy yard work, such as chopping wood 
٭ Weight lifting ( vigorous effort) 
10. Carotid disease was classified as whether the stenosis is symptomatic or 
asymptomatic and by degree of stenosis (percentage narrowing of the narrowest 
segment compared to a more distal internal carotid segment). Symptomatic 
carotid disease implies that the patient has experienced a stroke or TIA with in 
the vascular distribution of the artery, and asymptomatic carotid disease implies 
that the patient was symptom free and the stenosis is detected through 
screening.     
11. Seizure (form the Latin sacire, “to take possession of) is a paroxysmal 
event due to abnormal, excessive, hypersynchronous discharges from an 
aggregate of central nervous system (CNS) neurons. Depending on the 
distribution of discharges, this abnormal CNS activity can have various 
manifestations, ranging from dramatic convulsive activity to experimental 
phenomena not readily discernible by an observer.   
Methods: 
 Relevant socio-demographic, clinical and laboratory data were collected 
from the patients and controls and recorded in a proforma (Appendix I). 
I. Socio demographic data comprised of : 
• Age 
 31
• Gender 
• History of tobacco smoking / alcoholism  
II. Clinical  data 
• Clinical examination.  
III Laboratory Data 
• Blood sugar fasting and post prandial / Urea / serum Creatinine  
• Lipid profile  
• ECG  
• Carotid doppler study  
• CT Scan / MRI Brain :  
• Automated complete Hemogram including platelet count and mean 
platelet volume  
 
 For the haematological evaluation, 2 ml of blood was drawn by 
venepucture after aseptic precaution and collected in EDTA coating disposable 
tubes from the patients within 30 minutes of admission to the hospital. The 
sample was transported immediately to a quality controlled centre where the 
sample was analysed for platelet volume. The instrument used for analysis was 
BECKMAN COULTER AC.T 5 DIFF 5 PART FULLY automated 
haematological analyzer which was repeatedly standardized for BIORAO three 
level quality control.  
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Conflict of interest: 
 There was no conflict of interest. 
Financial support: 
 Nil 
Limitations: 
1. Technical constraints and cost factor of the investigation have led to 
limited number of cases. 
Statistical Analysis: 
 Data collected were entered in Microsoft excel spread sheet and analysed 
utilizing the software-Epidemiological Information Package 2002 (Epi Info 
2002) - developed by the centre for disease control and prevention, Atlanta for 
World Health Organisation and SPSS ver 15.0 was also used for the analysis. 
Range, Median, Mean and Standard deviation and ‘p’ values were calculated 
using this package. Chi squared test was used for binary and categorical data. 
Independent sample t-test and ANOVA were also used accordingly to test the 
significance between case and control groups.   
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OBSERVATION AND RESULTS  
 
 The total number of subjects included in the study was 100. Among the 
100 subjects 50 were cases under study and 50 were controls and their profile is 
furnished below. 
Age Distribution  
 The distribution of cases and controls with respect to age is given in 
Table – 1 given below. 
Table – 1 
Distribution of cases and controls with respect to age   
Case Control Age Groups 
(years) No % No % 
< 45  9 18 34 68 
> 45 41 82 16 32 
Range  30-88 21-67 
Median  56.50 38.50 
Mean  56.74 40.02 
S.D 12.53 10.82 
 p value = .0001 (significant)  [chi-square] 
 
There was statistically significant difference with respect to age among them. 
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Gender Composition  
Table 2   
 
Distribution of cases and control with respect to gender   
 
Case Control  
Gender 
No % No % 
Males  41 82 30 60 
Females  9 18 20 40 
 
p value = .015 (significant)  [Chi-square] 
 
 The difference in the gender composition of case and control group was 
statistically significant.   
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Weight, Height and Body mass index  
 Among the 50 cases, anthropometric indices was recorded in 24 cases 
only.  
Table – 3 
Distribution of cases and controls in relation to weight in kg, Height in cms 
and body mass index 
Status No Range Mean S.D ‘p’ value 
Case  24 (48%) 40-82 61.04 11.18 Weight 
in kgs Control  50 46-97 66.50 11.24 
.0882 (not 
significant)  
Case  24 (48%) 150-176 161.17 7.1 Height 
in cms  Control  50 152-187 165.94 7.85 
.0263 
(significant)  
Case  24 (48%) 16-31.3 23.35 3.53 Body 
mass 
index  
Control  50 16.6-
33.2 
24.19 3.84 
.445 (not 
significant)  
 
 There were no significant difference with respect to weight, height and 
body mass index among them. 
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Lipid Profile  
Table – 4 
Distribution of cases and controls in relation to Total cholesterol HDL, 
LDL and Triglyceride  
Status No Mean  S.D ‘p’ value 
Case  50 174.20 48.36 Total 
Cholesterol  Control  50 162.38 25.50 
.130 (not 
significant)  
Case  50 37.42 7.57 HDL 
Control  50 40.60 9.96 
.075 (not 
significant)  
Case  50 112.98 38.72 LDL 
Control  50 93.26 28.86 
.118 (not 
significant)  
Case  50 126.12 59.1 Triglyceride  
Control  50 93.26 28.86 
0.001(significant)  
Case  50 4.71 1.18 Total 
Cholesterol 
HDL ratio 
Control  50 4.14 0.72 
0.0364 
(significant)  
 [t test] 
 
 There were no significant differences with respect to total cholesterol, 
HDL, and LDL among them. There were significant difference with respect to 
triglyceride and total cholesterol / HDL ratio among them. 
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RBC count, WBC count and MCV 
Table – 5 
Distribution of cases and controls in relation to RBC count, Mean 
Corpuscular volume, and WBC counts 
  
Status No Mean S.D ‘p’ value 
Case  50 4.56 0.68 RBC counts 
in 
million/cumm Control  50 4.79 0.54 
0.072 (not 
significant)  
Case  50 83.86 8.15 MCV 
Control  50 83.02 7.43 
.60 (not 
significant)  
Case  50 10910 4857.83 WBC count 
in cumm Control  50 7228 1458.97 
.0001 
(significant)  
 [t test] 
 
 There were no statistically significant difference with respect to RBC 
count and MCV. There was statistically significant difference with respect to 
WBC count among them. 
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Platelet Count: 
 
Table – 6 
Distribution of cases and controls in relation to platelet count  
 
Status No Mean S.D ‘p’ value 
Case  50 2.52 06 Platelet count 
laksh in 
cumm 
Control  
50 2.88 .64 
.004 
(significant) 
[t test] 
 
 The mean and standard deviation for platelet count of cases were 2.52 ± 
0.6 lakh/cumm and those for controls were 2.88 ± 0.64 lakhs/cumm. The 
difference in platelet count of cases and control group was statistically 
significant. 
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Mean Platelet Volume  
Table – 7 
Distribution of cases and controls in relation to Mean platelet Volume (f1)     
95% CI for 
mean 
Status No Range Mean S.D 
Lower 
bound 
Upper 
bound 
‘p’ value 
Case 50 6.5-9.6 7.81 .79 7.591 8.031 
MPV 
(f1) Control 50 6.4-8.8 7.62 0.54 7.463 7.769 
0.145 (not 
significant) 
using 
ANOVA 
 
 The range of MPV among cases were 6.5 – 9.6f1 and controls were 6.4 – 
8.8 f1. Even though the mean MPV was higher in case than control it was not 
statistically  significant.  
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Platelet count and MPV 
 
Table – 8 
Correlation between platelet count and mean platelet volume with in 
controls  
Status 
Platelet count 
lakhs in cumm 
Mean platelet 
volume 
Pearson 
correlation  
1 -.279* 
Sig (2 
tailed) 
 .050 
 
Platelet count 
laksh in cumm 
N 50 50 
Pearson 
correlation  
-.279* 1 
Sig (2 
tailed) 
.050  
 
Mean Platelet 
Volume (f1) 
N 50 50 
 Control -.279* significant 
 The negative correlation between platelet count and MPV with in 
controls was statistically significant. 
 The negative correlation between platelet count and MPV with in cases 
was not statistically significant.  
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Table – 9 
Correlation between platelet count and mean platelet volume with in cases 
Correlation is significant at the 0.05 level (2 tailed) 
 
 Status Platelet count 
lakhs in cumm 
Mean platelet 
volume 
Pearson 
correlation  
1 -.190 
Sig (2 
tailed) 
 .187 
 
 
Platelet count 
laksh in cumm 
N 50 50 
Pearson 
correlation  
-.190 1 
Sig (2 
tailed) 
.187  
Mean Platelet 
Volume (f1) 
N 50 50 
 
 Case – Not significant  
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RELATIONSHIP BETWEEN MPV AND OTHER PARAMETERS  
Table – 10 
Relationship between Age & MPV 
MPV Values Age group 
No Range Median Mean S.D 
< 45 9 (18%) 7.0 – 9.6 7.7 8.04 .88 
> 45 41 (82%) 6.5 – 9.6 7.9 7.76 .77 
 ‘p’ value = .336 (not significant) 
 The relationship between age and MPV is not statistically significant  
Table – 11 
Relationship between gender & MPV 
MPV Values Gender 
No Range Median Mean S.D 
Males  41 (82%) 6.5-9.6 7.9 7.89 .81 
Females  9 (18%) 6.7-8.3 7.4 7.48 .61 
 ‘p’ value 0.158 (not significant)  
 The mean MPV for Males was 7.89 f1. the mean MPV for females was 
7.48 f1. MPV was found to be independent for gender. 
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Table – 12 
Relationship between types of stoke & MPV 
MPV Values Types of 
stroke No Mean S.D 
Ischemic  41 (82%) 7.72 0.67 
Hemorrhagic  9 (18%) 8.26 1.12 
  ‘p’ value = 0.2874 (not significant) [t test] 
  
 There was no statistically significant difference between the Ischemic 
stroke and Hemorrhagic stroke . 
Table  - 13 
Relationship between Territory (ischemic) & MPV 
MPV Values Territory 
(ischemic) No Mean S.D 
Middle cerebral 
artery  
27 
(66%) 
7.68 0.73 
Posterior 
cerebral artery 
2 (5%) 8.05 .35 
Anterior 
cerebral artery 
- - - 
Vertebro  
basilar artery 
7 (17%) 7.66 0.63 
Multiple artery  4 (10%) 7.98 0.59 
  ‘p’ value = 0.5413 (not significant) [ANOVA] 
 There was no statistically significant difference between the area of the 
ischemia and mean platelet volume. 
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Table - 14 
Relationship between Region (Hemorrhage) and MPV 
  
MPV Values Region 
(haemorrhage) No Mean S.D 
Basal Gamglia 5 (55%) 8.06 1.04 
Cortex  - - - 
Thalamas  3 (34%) 8.7 1.56 
Pons  - - - 
Cerebellum - - - 
Others  1 (11%) 7.9 - 
Multiple  - - - 
  ‘p’ = .1188 (not significant) 
 
  There was no significant difference between the area of the hemorrhage 
and mean platelet volume.  
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Table – 15 
Relationship between recurrence of stroke & MPV 
MPV Values Recurrence of stroke 
No Mean S.D 
YES 7 (14%) 7.53 .96 
No 43 (86%) 7.86 .75 
 
 ‘p’ = .305 (not significant) 
 Among 50 cases, 7 cases were recurrence of stroke and 43 cases were 
first episode of stroke. The mean MPV in cases with previous history of stroke 
was 7.53 ± 0.96fl. The mean MPV in first episode of stroke was 7.86 ± 0.75fl.  
 The relationship between recurrence of stroke and MPV was not 
statistically significant. 
Table - 16 
Relationship between Hypertension & MPV 
MPV Values Systemic 
Hypertension No Mean S.D 
YES 27 (54%) 7.76 0.71 
No 23 (46%) 7.87 0.88 
 ‘p’ = .624 (not significant) [t test] 
There was no significant relationship between systemic hypertension and MPV. 
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Table - 17 
Relationship between Diabetes Mellitus and MPV 
 
MPV Values Diabetes 
Mellitus No Mean S.D 
YES 19 (38%) 7.76 .72 
No 31 (62%) 7.85 .83 
 
 ‘p’ = .724 (not significant) [t test] 
 
 The relationship between diabetes and MPV was not statistically 
significant. 
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Table - 18 
Correlations between lipid profile & MPV 
 
 Mean 
platelet  
volume 
(f1) 
Total 
cholesterol 
HDL LDL Triglyceride 
Pearson 
correlation  
1 .076 -.015 -.002 .091 
Sig (2 
tailed) 
 .598 .915 .992 .531 
Mean 
Platelet 
volume (f1) 
N 50 50 50 50 50 
Pearson 
correlation  
.076 1 .392 .906 .337 
Sig (2 
tailed) 
.598  .005 .000 .017 
Total 
Cholesterol  
N 50 50 50 50 50 
Pearson 
correlation  
-.015 .392 1 .253 .009 
Sig (2 
tailed) 
.915 .005  .076 .949 
HDL 
N 50 50 50 50 50 
Pearson 
correlation  
-.002 .906 .253 1 .332 
Sig (2 
tailed) 
.992 .000 .076  .018 
LDL 
N 50 50 50 50 50 
Pearson 
correlation  
.091 .337 .009 .332 1 
Sig  
(2 tailed) 
.531 .017 .949 .018  
Triglycerides 
N 50 50 50 50 50 
  
 There was no correlation between lipid profile and mean platelet volume. 
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Table - 19 
Relationship between recent myocardial infarction & MPV 
MPV Values Recent 
myocardial 
infarction 
No Mean S.D 
YES 4 (8%) 7.8 0.52 
No 46 (92%) 7.82 0.81 
   ‘p’ = .971 (not significant) [t test] 
 There was not significant difference between recent myocardial 
infarction and MPV  
Table - 20 
Relationship between Valvular Heart Disease & MPV 
MPV Values Valvular 
Heart 
disease No Mean S.D 
YES 1 (2%) 8.2 - 
No 49 (98%) 7.81 .79 
  ‘p’ = .625 (not significant) 
 The relationship between valvular heart disease and MPV was not 
statistically significant. 
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Table - 21 
Relationship between smoking & MPV 
MPV Values Smoking 
No Mean S.D 
YES 15 (30%) 8.14 .86 
No 35 (70%) 7.67 .72 
   ‘p’ = .054 (Significant)  [t test] 
 Among the 50 cases, 15 cases were smokers and 35 cases were non 
smokers. The mean MPV among smokers was 8.14 f1. The mean MPV among 
non smokers was 7.67 f1. A significant relationship between smoking and MPV 
was noted. 
Table - 22 
Relationship between Alcohol & MPV 
MPV Values Alcohol 
abuse  No Mean  S.D 
YES 19 (38%) 8.12 .69 
No 31 (62%) 7.63 .79 
  ‘p’ = .032 (Significant) [ t test] 
 Among 50 cases 19 cases were alcoholic and 31 cases were non-
alcoholic. The mean MPV among alcoholic was 8.12 f1. The mean MPV 
among non alcoholic was 7.63 f1. There was significant relationship between 
alcohol and MPV. 
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Table - 23 
Relationship between physical activity & MPV 
MPV Values Physical 
activity  No Mean  S.D 
YES 48 (96%) 7.83 0.80 
No 2 (4%) 7.50 .28 
  ‘p’ = .569 (not significant) [ t test] 
 There was no significant relationship between physical activity and MPV 
Table - 24 
Relationship between carotid stenosis & MPV 
MPV Values Carotid Stenosis  
No Mean  S.D 
> 70% occlusion 2 (4%) 8.9 0.42 
< 70% occlusion  25 (50%) 7.59 0.64 
  ‘p’ = .05 significant  (ANOVA) 
 Among 41 cases of ischemic stroke, in 27 cases Carotid doppler study 
was done. Two cases had more than 70% carotid occlusion and 25 cases had 
less than 70% carotid occlusion. 
 There was a statistical significance noted between carotid stenosis and 
MPV    
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Table - 25 
Relationship between Hemorrhagic transformation of Infarction & MPV 
MPV Values Age 
transformation 
of  Infection  
No Mean  S.D 
YES 4 (8%) 7.03 0.41 
No 39 (78%) 7.74 .68 
   ‘p’ = .0009 (significant) (ANNOVA) 
Among 50 cases, 4 cases had hemorrhagic transformation of infarction, 39 
cases had no hemorrhagic transformation. The mean MPV for hemorrhage 
transformation of infarction was 7.03 f1. The mean MPV for patients with pure 
infarction with no haemorrhage transformation was 7.74 f1. There was a 
statistically significant relationship between hemorrhagic transformation of 
infarction and MPV. 
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Table - 26 
Relationship between Aspirin & MPV  
MPV Values Aspirin 
medication 
before 
admission  
No Mean  S.D 
YES 13 (26%) 7.58 .82 
No 37 (74%) 7.90 .77 
   ‘p’ = .3857 (not significant) [t test] 
   No significant relationship between aspirin medication before 
admission and MPV was noted 
 
Table - 27 
Relationship between clopidogrel & MPV 
MPV Values Before 
admission 
clopidogrel 
intake  
No Mean  S.D 
YES 9 (18%)  7.79 .87 
No 41 (82%) 7.82 .78 
 ‘p’ = .0232 (Not significant) [t test] 
No significant relationship between clopidogrel intake before admission 
and MPV 
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Table - 28 
Relationship between LMW Heparin & MPV 
MPV Values  
Before admission LMW Heparin  
No Mean  S.D 
YES 3 (6%) 8.2 .95 
No 47 (94%) 7.79 0.78 
  ‘p’ = .6047 (not significant) [t test] 
Table - 29 
Relationship between Regular Heparin & MPV 
MPV Values  
Before admission Regular Heparin  
No Mean  S.D 
YES 2 (4%) 8.75 .64 
No 48 (96%) 7.78 .77 
  ‘p’ = .2035 (not significant) [t test] 
Table - 30 
Relationship between Warfarin & MPV 
MPV Values  
Before admission Warfarin  
No Mean  S.D 
YES 1 (2%) 8.3 - 
No 49 (98%) 7.86 .79 
  
 No significant relationship between LMW heparin, regular heparin and 
warfarin with mean platelet volume.  
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Table – 31  
Relationship between Inj. Mannitol  & MPV 
MPV Values  
Before admission injection mannitol  
No Mean  S.D 
YES 6 (12%) 8.4 .69 
No  44 (88%) 7.76 .79 
 ‘p’ = .2788 (not significant) [t test] 
Table - 32 
Relationship between Glycerol & MPV 
MPV Values  
Before admission Glycerol  
No Mean  S.D 
YES 3 (6%) 8.53 .6 
No 47 (94%) 7.77 .80 
  ‘p’ = .1675 (not significant) [t test] 
Table - 33 
Relationship between Statin & MPV 
MPV Values  
Before admission Statin 
No Mean S.D 
YES 8 (16%) 7.51 .80 
No 42 (84%) 7.87 .78 
  ‘p’ = .4003 (not significant)  [t test] 
  
 No significant relationship between injection mannitol, glycerol and 
statin with mean platelet volume. 
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Table - 34 
Relationship between Ramipril & MPV 
MPV Values  
Before admission Ramipril No Mean S.D 
YES 2 (4%) 6.7 .28 
No 48 (96%) 7.86 .77 
  ‘p’ = .0048 (Significant)  [t test] 
 Among 50 cases, two cases were on Ramipril before admission and 48 
cases were no Ramipril intake before admission  
Table - 35 
Control Vs Before admission Ramipril intake relation to mean platelet 
volume  
MPV Values  Status  No Mean S.D 
Control 50 7.62 0.54 
Before admission Ramipril  2 6.7 0.28 
 p value = .0130 (significant) [ t test] 
Table – 36 
Control Vs Before admission not taking Ramipril  
MPV Values  Status  No Mean S.D 
Control 50 7.62 0.54 
Before admission Not taking 
Ramipril  
48 7.86 0.77 
 p value = .2083 (not significant)  
 There was significant relationship between Ramipril use before 
admission and MPV 
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Table – 37 
Association between severity of stroke (modified Rankin scale) during 
admission and MPV   
MPV Values   
Severity of stroke mRS 
scale  No Range  Median  Mean  95% CI for 
mean  
S.D 
0-2 (upto slight disability)  5 (10%) 6.8-8.1 7.300 7.44 6.657-8.223 .63 
3-5 (moderate to severe 
disability)  
45 (90%) 6.5-9.6 7.900 7.860 7.616 – 8.095 .80 
 p value = .266 (not significant) [t test] 
 During admission patient with moderate to severe disability of the stroke 
had higher mean MPV than slight severity of stroke, but it was not statistically 
significant.     
Table – 38 
Association between stroke severity according to Glasgow out come score 
during discharge and MPV 
MPV Values  Severity of stroke as 
per Glasgow outcome 
score during  discharge   
 
No 
 
 
Range  
 
 
Median  
 
 
Mean  
 
95% CI for 
mean  
 
 
S.D 
5 (Good recovery) 13 (26%) 6.8 – 9.6 7.4 7.71 7.19-8.22 .85 
4 (moderate disability) 19 (38%) 6.5 – 9.2 7.9 7.77 7.38-8.16 .81 
3 (severe disability  15 (30%) 7.0 – 9.6 7.9 7.94 7.57-8.31 .67 
2 (Persistent vegetative 
state  
3 (6%) 6.5 – 8.8 8.4 7.9 4.85 – 10.95 1.23 
1 (Death) 0 - - - - - 
 
 During discharge the patient with severe disability of stroke had higher 
mean MPV than good recovery of stroke, but it was not statistically significant.      
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DISCUSSION 
  
 Stroke is a world wide social and health problem. It makes an important 
contribution to morbidity, mortality and disability in developed as well as 
developing countries like India. Endogenous and exogenous risk factors like 
systemic hypertension cardiac abnormality, diabetes mellitus, dyslipidema, 
obesity and smoking significantly increase the risk for stroke. However they 
only explain part of the problem and in some of the cases there may be other 
relevant risk factors which need to be identified and addressed.  
 Bath et al (2004) found that mean platelet volume (MPV) is an 
independent risk factor for stroke. Similar observations were made by O’ 
Malley et al (1995) and Greisenegger et al (2004). Large platelets are more 
reactive, produce more thrombotic factors (Martin et al, 1982) and aggregate 
more easily (Haver et al, 1981). However most studies are from the west with 
healthy western people serving as controls. An attempt was made in present 
study to find out if any association existed between the platelet size and 
occurrence of stroke among the local population. Currently, no data are 
available regarding this aspect among Indian population.  
   In this study, the age of the cases ranged from 30-88 years. The mean 
was 56.74 ± 12.53 years. Maximum number of cases i.e. 41 cases fell in the age 
above 45 years (82%). This is in parallel with the observation made by Henry et 
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al (1998) and Park K (2005). This may be probably due to ongoing 
atherosclerosis as age advances.  
 Available literature on association between age and MPV is 
contradictory with evidences showing both an increase in MPV with age as 
observed by Funiak et al and also decrease in MPV with age shown by Bancroft 
et al. In the present study no statistically significant relation was noted between 
age and MPV and similar to the observation also made by Von Behren et al. 
While advancing age is associated with increased incidence of stroke and 
increased mean platelet volume also increased the incidence of stroke, the lack 
of direct association between increasing age and MPV is interesting yet 
puzzling. Presumably the smaller sample size in our data was responsible for 
this observation.     
 Among 50 cases, there were 41 men (82%) and 9 (18%) women. Park K 
(2005) noted that incidence rates are higher in males than females at all ages. 
This gender difference is due to different vascular risk factor profile among 
men and women namely alcoholism and smoking for men, hypertension and 
cardio embolism for women. Gender specific incidence rate converge after 
menopause suggesting a major role for estrogen in delaying progression of 
atherosclerosis. Much of this effect results from beneficial action of estrogen on 
lipid fraction. Estrogen reduces LDL – C by 10-15% while increasing HDL-C.  
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   In the present study MPV was independent of gender. Bancroft et al 
(2000) noted that MPV was independent of gender. Our study confirms the 
observation made by the above author.  
 In our study, among 50 cases, 41 cases (82%) had ischemic stroke and  9 
(18%) had hemorrhagic stroke. Henry JM et al (1998) observed that 70% of 
stroke cases were ischemic in nature and 27% were hemorrhagic. Furlan et al 
(1979) had also noted that the incidence of primary hemorrhagic stroke was 
low. Our study is in parallel with these observations. In our study incidence of 
hemorrhagic stroke was low. This may be due to early detection and treatment 
for systemic hypertension which is the most common cause of intracerebral 
hemorrhage.    
 In our study though the mean of MPV was higher in the hemorrhagic 
strokes than ischemic strokes. This difference was not statistically significant. 
Bath et al (2004) found values of MPV for ischemic stroke were higher and 
there was no evidence of association of MPV with either intracerebral 
hemorrhage (or) stroke of unknown etiology.  Eldor A et al (1982) had noted 
that increase in MPV, reduced the occurrence of hemorrhage stroke 
contradictory to our findings  
 Among the 41 cases of ischemic stroke. 
  27 cases (66%) had middle cerebral artery infarct  
  2 cases (5%) had post cerebral artery infarct  
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  7 cases (17%) had vertebro  basilar territory infarct  
  4 cases (10%) had multiple vessel infarction and   
  1 case (2%) had cerebral venous thrombosis  
 No patients had anterior cerebral artery infarct. Middle cerebral artery is 
a direct branch of internal carotid artery. This artery is most vulnerable for 
thrombo embolic infarction rather than other branches of internal carotid artery 
Adam et al (1961). There was no statistically significant difference between the 
territory ischemic involvement and MP. It is thus unlikely that platelet 
consumption at any particular thrombus site would affect the peripheral venous 
estimation of platelet variable.   
 In our study, among 9 cases of hemorrhagic stroke, the lesions were 
localised in the following areas of the brain.  
  5 cases (55%) had basal ganglionic involvement  
  3 cases (34%) had thalamic involvement  
  1 cases (11%) present with primary intra ventricular hemorrhage  
 In general basal ganglion is the commonest area involved in hemorrhagic 
stroke Wade et al (2005). There was no statistically significant relationship 
between the region of hemorrhage and MPV.  
 In our study, 17 cases had right hemispherical lesion, 28 cases had left 
hemispheric lesion and 5 cases had bilateral hemispheric involvement of both 
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the hemisphere. Common carotid artery occlusion by atheromatous plaque at its 
origin was seen more often on the left side (Ropper et al).     
 In the present study among 50 cases, 7 cases (14%) had presented with 
recurrence of stroke. There was no statistically significant relationship between 
recurrence of stroke and MPV. O’Malley et al observed that there was no 
significant difference in MPV in patients with previous history of stroke 
compared to patients with no previous stroke. Our finding runs in parallel with 
this observation. Thus it may be inferred that increase in MPV could influence 
the occurrence of stroke, but not whether there could be recurrence. Thus 
targeting therapeutic strategy in future to reduce the MPV may not be useful in 
the secondary prevention of stroke though this could be of value in the primary 
prevention.        
 Duration between onset of stroke to seek medical help, ranged between 
10 minutes to 2880 minutes. Mean ± SD was 175.80 ± 563.27 minutes. 
Duration between onset of stroke to reach tertiary care hospital ranged between 
30-4320 minutes. Mean ± SD was 1217.50 ± 1243.66 minutes.   
 In our study, the reasons for delay were as follows  
  84% due to local hospital treatment   
  12% due to transport delay  
  4% due to financial problems 
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 Bath et al (2004) study showed that the time of MPV measurement, the 
time of occurrence of stroke or delay between blood collection and 
measurement of MPV did not alter the MPV significantly.  
 
 Distance traveled to reach the tertiary hospital ranged between 2-200km. 
Time interval from onset of stroke to take CT/MRI scan of brain ranged from 
40-2940 minutes. Door to aspirin / clopidogrel timed ranged from was 110-960 
minutes. Among the stroke patients, 27 cases (54%) had systemic hypertension. 
The prevalence of systemic hypertension in stroke was 80.8% in the 
Framingham study 1950.  In general with systemic hypertension there was 
50% chance of increase risk for stroke. Systemic hypertension was responsible 
worsening of atherosclerosis.   
 However in the present study, no statistical relationship was observed 
between systemic hypertension and MPV. Bath et al (1996) had earlier made 
observation similar to our study. Osuna et al (1998) and Cardee et al (1981) 
observed a higher MPV in those with systemic hypertension presenting with 
acute myocardial infarction. This may be due to change is megakarocyte 
processing and thrombopoietin in response to change in vascular function in 
hypertension. 
Despite atherosclerosis being common for both acute myocardial 
infarction and stroke, whether regional difference in the target organ damaged 
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contributed to such a discrepancy is not known as our study was done on stroke 
while Osuna et al reported on myocardial infarction.    
Nineteen patients (38%) in the present study had diabetes mellitus. 
However the MPV of patients with diabetes mellitus did not vary from those 
without diabetes mellitus. Sharke et al (1993) noted that MPV was significantly 
increased in diabetic subjects compared with nondiabetic. They stated that since 
the platelet size is a determinant of platelet function, with larger platelets being 
more reactive per unit volume, the platelets might play a part in the micro and 
macro vascular complications of diabetes mellitus.  
Osuna et al (1998) also observed a higher MPV with diabetes mellitus. 
This may be due to diabetes related stem cell dysfunction of megakaryocytic 
series and its progenitor cells resulting in increased MPV and reactivity. The 
fact that in our study no relationship was observed may be due to the small 
sample size. Whether the degree of diabetic control could have influenced this 
effect was not specifically looked of in this study.    
 Kario et al (1992) had reported that hypercholesterolemia was associated 
with increase in MPV. In our study no correlation existed between lipid profile 
and MPV. Thus MPV may be considered as on independent risk factor for 
stroke. This is also strengthened by our observation that use of statin did not 
influence MPV. A positive correlation between total cholesterol with HDL, 
LDL and triglyceride was found in the present study. There was no correlation 
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between HDL, with LDL and triglyceride. There was positive correlation 
between LDL and triglyceride. Greisenegger et al (2004) found that there was 
no significant correlation between MPV and serum cholesterol and triglyceride 
levels.  
 In the present study 4 cases (8%) had recent myocardial infarction. All 4 
cases involved the anterior myocardial wall. In general population  2-6% of 
stroke cases were due to emboli from left ventricle mural thrombus which was 
not detected by echo in 40% of cases of anterior myocardial infarction.      
 Martin et al (1983) and Cameron et al (1983) found an association 
between increased mean platelet volume and increased occurrence of 
myocardial infarction. However studies conducted by Halbmayer et al (1995) 
and Bath et al (2004) showed that coronary event rates were not associated with 
MPV. Our finding runs in parallel with that of Halbmayer et al (1995) and Bath 
et al (2004). The absence of an association of MPV with coronary events could 
reflect a true lack of association in this study population. A more likely 
explanation is that the small number of coronary events provided only limited 
statistical power to detect the true association of MPV with coronary disease.       
 Among 50 cases, fifteen (30%) were smokers. This shows an increased 
prevalence of smoking among patients with stroke and this was statistically 
significant. Wolf et al (1988) observed that cigarette smoking was a risk factor 
for stroke. Framingham study et al (1988) found a 50% increased risk of stroke 
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in smokers than non smokers. In smokers hemorrhagic stroke was two times 
more common than ischemic stroke. Smoking causes temporary increase in 
blood pressure which acting in concert with metastatic emphysema effect was 
responsible for subarachnoid hemorrhage from cerebral aneurysm.     
 MPV was higher among smokers compared to non smokers and this 
relationship was statistically significant. Tschope et al (1989) and Kario et al 
(1982) in separate studies found smokers to have an increased MPV. However 
Kishk et al (1985) observed no relation between smoking and MPV. Our 
finding runs in parallel with that of Tschope et al (1989) and Kario et al (1982). 
Smoking, due to direct stimulation of thrombopoietin production results in 
increased absolute count of reticulocyted platelet with higher MPV and 
containing higher concentration of p selection in per unit volume of platelet.   
 In the present study, 19 cases (38%) consumed alcohol, Gerelick et al 
(1989) found that alcohol was an independent risk factor for stroke. In the 
present study MPV was higher among who consumed alcohol and this effect 
was statistically significant. One explanation may be the coexistence of 
smoking with alcoholism, as MPV is known to be high in smoker. Donahue et 
al (1986) reported that alcohol consumption was related to hemorrhagic stroke 
than ischemic stroke and a ‘U’ shaped relationship between level of alcohol 
consumption and ischemic stroke. Minimal alcohol consumption or total 
abstinence and heavy alcoholic consumption were associated with increased 
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risk for stroke. Modest alcohol consumption reduced risk for stroke. Risk for 
hemorrhage stroke in patients who consumed alcohol was due to sudden 
increase in blood pressure on a background of sustained decrease in cholesterol 
level which weakened the vessel walls. Associated smoking also worsened this 
effect.  
 In our study 48 patients (98%) were physically active prior to onset of 
stroke. There was no statistically significant difference between physical 
activity and MPV, which may be due to the small sample size. Physical activity 
exerts a beneficial influence on risk factors for atherosclerosis.   
In our study, 2 cases (4%) had symptomatic carotid stenosis with more 
than 70% occlusion. There was statistically significant difference between 
carotid stenosis and MPV. In the general population, 5% of carotid 
atherosclerosis cause ischemic stroke (Wade S et al).  
 Among 40 cases with ischemic stroke, 4 (8%) developed hemorrhagic 
transformation of the infarct. Among these 4 cases, one case had cerebral 
venous thrombosis and other 3 patients had been already on aspirin medication 
for previous stroke. There was significant statistical relation between 
hemorrhagic transformation of infarction and MPV. This observation is 
clinically relevant as this may guide the clinician to be proactive in following 
patients with acute ischemic stroke to look for hemorrhagic transformation   in 
those with increased MPV. 
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 Among 50 cases, 13 had taken aspirin before admission. There was no 
significant relationship between those who had aspirin intake before admission 
and MPV.   
 Pizulli et al (1988) stated that aspirin has no effect on platelet volume. 
Contrary to their observation Bath et al (2004) found marked differences in of 
MPV with use of antiplatelet therapy. The difference in MPV between 
participants who were on or off antiplatelets were small in the present study. 
Greisenegger et al (2004) also found that patients on prior aspirin medication 
had significantly higher MPV values, possibly because of a higher vascular 
premorbidity. Aspirin increases the MPV by inhibiting cyclooxygenase 
pathway which influences the metabolic and signaling aspect of ‘p’ selectin in 
the megakarocyte.     
 Among 50 cases 9 had taken clopidogrel before admission. There was no 
statistically significant relationship between clopidogrel intake and MPV. In 
vitro studies have revealed that clopidogrel inhibits the ADP induced increase 
in MPV Greiseneger et al 2004.  
 Among 50 cases, 3 were on low molecular weight heparin, 2 were on 
regular heparin and one was on warfarin before admission. There were no 
significant relationships between LMW heparin, regular heparin, and warfarin 
with MPV. Thus while heparin is known to be associated with 
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thrombocytopenia no effect was noted on the volume of the individual 
megakaryocyte.  
 Among 50 cases, 5 were on injection mannitol and 3 had received 
glycerol before admission. No significant relation was found between the use of 
injection mannitol and glycerol and MPV.  
 Among 50 cases 8 were on statin before admission. Association between 
MPV and statin usage was not statistically significant.  
 Among 50 cases 2 were found to have been on ramipril before 
admission, and this had a statistically significant relationship with MPV. Bath 
et al (2004) noted that the antiplatelet activity of perindopril and other ACE 
inhibitors appear to have little effect on MPV.     
 In the present study use of ramipril was noted to decrease MPV 
significantly an observation made in both the stroke population and healthy 
controls. Thus this drug may have an independent effect in influencing stroke 
severity.  
 In the present study, distribution of cases and controls in relation to RBC 
count and mean corpuscular volume were not statistically significant.  
 However the distribution of cases and controls in relation to WBC count 
was statistically significant. Gresienegger et al (2004) stated that no significant 
correlation existed between MPV on admission and leukocyte count. Bath et al 
(2004) observed that severe stroke was associated with increased WBC counts. 
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Findings of the present study run in parallel with the observation made by the 
latter author.  
 Gilea et al (1984) observed that not all acute illness are associated with 
raised MPV. This may be due to some of the cytokines like interleukin 3, 
Granulocyte megakaryocyte colony stimulating factor may influence both 
megakaryocyte progenitor and myeloid progenitor at bone marrow level.   
 The mean platelet count of cases in this study was 2.52± .06 lakhs/mm3 
and that of control was 2.82± .64 lakhs /mm3 a difference that was statistically 
significant. O’Malley et al (1994) stated that platelet count was reduced in 
stroke patients compared with control groups. MPV was higher in acute stroke 
compared with control subject.  
   Greisenegger et al (2004) observed a slight but significant negative 
correlation between MPV and mean platelet count. There was negative 
correlation between platelet count and MPV among controls and this was 
statistically significant. There was a similar negative correlation between 
platelet count and MPV within cases, though this observation did not reach the 
level of statistical significance.  
 O’ Malley et al (1994) observed that there was a significant negative 
correlation between platelet count and MPV in stroke patients. It was 
statistically significant. There was no such correlation between platelet count 
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and MPV in control subjects. Although MPV among cases was higher 
compared to control it was not statistically significant.  
O’Malley et al (1995) conducted a similar study of MPV estimation in 
stroke patients. They estimated MPV in stroke patients within 48 hours of 
admission and also at 6 months follow up and compared it with controls. They 
found that MPV was significantly raised in stroke patients compared to 
controls. They suggested that the changes in MPV might have preceded the 
vascular event and is unlikely to be due to platelet consumption at the infarct 
site. They said that since the average life span of the platelets is about 8 days, 
the elevated MPV seen within the first 48 hours after stroke represented 
platelets released before infarction. Furthermore it was unlikely that platelet 
consumption due to the localized thrombosis would affect peripheral venous 
estimation of platelet variables. They further stated that since there was no 
difference in MPV between large cortical strokes and small lacunar infarcts, it 
was unlikely that platelet consumption at the thrombus site would affect the 
peripheral venous estimation of platelet variables. They also added that the fact 
that the observed increase in MPV had remained unchanged in post stroke 
survivors was further evidence that changes in MPV were likely to have 
preceded the acute event. 
 Bath et al (2004) conducted a similar study of MPV estimation in stroke 
patients. MPV was positively associated with occurrence stroke and 
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measurement of MPV may add useful prognostic information for clinician 
managing patients with history of cerebrovascular disease. This study 
concluded that there was no clear association of MPV with risk of major 
coronary events. However it is to be acknowledged that the small number of 
coronary events provided only limited statistical power to detect the true 
association of MPV with coronary events. 
 During admission, patients with moderate to severe disability due to 
stroke (modified Rankin Scale 3-5) had higher MPV than patients with lesser 
disability due to stroke (mRS 0-2) however this was not statistically significant. 
During discharge patient with moderate to severe disability due to stroke had 
higher MPV then those who made good recovery, through this differences was 
not statistically significant.  
 Our observation are in contrast to this by  Greisenegger et al (2004) who 
noted that elevated MPV is associated with worst outcomes for acute ischemic 
cerebrovascular events independent of other clinical parameters.  In severe 
stroke, increased MPV reflects higher platelet reactivity before stroke has 
occurred.  O Framo et al (1990) and O’ Malley et al (1999) stated that no 
relationship existed between MPV and stroke outcome. Possible reasons for 
these divergent results could be the small number of patient and the use of 
different outcome measures in these studies.  
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 Thus it may be concluded that while the occurrence of stroke may be 
influenced by MPV, severity of stroke at admission or discharge is independent 
of the degree of elevation of MPV. Thus MPV may not be useful as prognostic 
marker following stroke.    
Strengths, Limitations and future recommendation    
 This study is the first to address to role of MPV in stroke population in 
India . Ethnic differences in stroke being well established, this may provoke 
future research to understand the significant is that MPV in the pathogenesis of 
stroke in a large context. Small sample size was the major limitation in this 
study however.    
 Areas of further work  
1. MPV studies in other thrombotic episodes  
2. Follow up study on MPV after the onset of clinical events. 
3. Platelet volume studies among patients on losartan and doxasosin.  
4. In vitro studies on factors contributing for thrombomegaly in order to 
introduce interventional measures  
5. Studies to find out the physiological measurements which regulate MPV 
within the megakaryocyte.  
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SUMMARY 
 The study ‘mean platelet volume in cerebro vascular disease’ was 
undertaken to assess the relationship between mean platelet volume (MPV) and 
various aspects of stroke. Fifty patients who presented with stroke to a tertiary 
care hospital were studied. The demographic, clinical and laboratories data of 
these patients were recorded. The relationship between mean platelet volume 
and the type of stroke, age, gender, conventional risk factor and treatment 
aspects were analysed. MPV in these patients were compared to controls who 
were age and gender matched.  
There was no significant relationship between age, gender, type of 
stroke, territory of arterial involvement in ischemic stroke, region affected in 
hemorrhage stroke, recurrence of stroke, systemic hypertension, diabetes 
mellitus, recent myocardial infarction, valvular heart disease, physical activity 
with MPV. 
There was significant negative correlation between platelet count and 
MPV in control groups. In cases there was negative correlation between platelet 
count and mean platelet volume but it was not statistically significant. 
MPV was higher with smoking, alcohol use and carotid stenosis more 
than 70%. MPV was lower than normal in patients with hemorrhagic 
transformation of infarction and with intake of ramipril in the cases. No 
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significant relationship between intake of drugs like aspirin, clopidogrel, LMW 
heparin, regular heparin, warfarin, statin, injection mannitol and oral glycerol 
with MPV.   
The mean platelet count in cases 2.52± 0.06 lakh/mm3 and the mean 
platelet count in control 2.88±0.64lakh/mm3 (p=.004 statistically significant). 
The MPV of the patients ranged from 6.5-9.6 femtolitres and controls ranged 
from 6.4-8.8 femtolitres. The Mean and SD of MPV of the patient was 7.81±..7 
femtolitres and that of control was 7.62±0.54 femtolitres. This was not 
statistically significant (p=.315). The mean value of mean platelet volume was 
higher among the patients with haemorrhagic stroke compared to those with 
ischemic stroke, though the difference was not significant.  
MPV was higher in patients with moderate to severe disability due to 
smoke than those with lesser disability due to during admission as well as 
discharge following acute care. This was not statistically significant.  
Pathophyiology of increased MPV may need to be further elucidated and 
its clinical bearing has to the studied involving larger studies.  
Further research is required into the role of platelet volume in stroke 
pathology and outcome and also importantly in influencing the individual risk 
factors of stroke. Whether MPV becomes a routinely requested test remains to 
be seen.             
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CONCLUSION 
 
• MPV was elevated in the patients with stroke when compared to control 
in a non significant manner.  
 
• The mean value of mean platelet volume was higher among the patients 
with haemorrhagic stroke compared to those with ischemic stroke, 
though the difference was not significant.  
 
• MPV was higher among the patients with moderate to severe disability 
of stroke than patients with slight disability of stroke in a non significant 
manner.  
 
• There was significant negative correlation between platelet counts and 
MPV in controls. In cases also there was negative correlation between 
platelet counts and MPV though it was not significant.  
 
• There was no correlation between lipid profile and MPV in cases.  
 
• MPV was higher among smokers, alcoholics and patients with  carotid 
stenosis  more than 70% occlusion.  
 
• MPV was lower among the patients with  hemorrhagic transformation of 
infarction and Ramipril intake.  
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• MPV in patients with stroke was found to be independent of age, gender, 
type of stroke, territory of ischemia, region of hemorrhage, recurrence of 
stroke, hypertension, diabetes mellitus, recent myocardial (ischemic) 
infarction, valvular heart disease, physical activity, drugs like aspirin 
clopidogrel, LMW heparin, regular heparin, warfarin, injection mannitol, 
oral glycerol and statin.   
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MEAN PLATELET VOLUME IN STROKE –  
CASE STUDY  
 
Sl. No.  
Hospital No. 
Name  
Age  
Gender  
 
Type of stroke  
 
Territory (Ischemic)  
 
 
 
 
 
 
Region (Hemorrhage) 
 
 
 
 
 
 
  
 
Hemisphere 
 
 
Recurrence of stroke  
 
M 1  
 
F 2  
Ischemic  1  
 
Hemorrhagic  2  
 
MCA 1  
 
PCA 2  
 
ACA 3  
 VBI 4  
 
Multiple  5  
 
Basal Ganglia  1  
 
Cortex  2  
 Thalamus  3  
 
Pons    4  
 
Cerebellum   5  
 
Others    6  
 
Multiple  7  
 
R  1  
 
L  2  
 
Y  1  
 
N  2  
 
 
 
Not 
applicable  
9  
 
Not 
applicable  
9  
 
Both  3  
 
 Duration between onset of stroke to seeking medical help first (minute) 
Duration to reach Territory Hospitals – Madurai (minute) 
Reason for delay  
 
 
 
 
Distance from Territory hospital  
Door to CT/MRI (minutes) 
 
Door to Aspirin / Clopidrogel (minutes) 
Hypertension  
 
HT (in year)  
 
 
Diabetes  
 
DM (in year) 
 
Dyslipidemia  
 
Recent myocardial infarction  
 
Valvular heart disease  
 
Atrial fibriliation  
 
Nutritional status (BMI) 
Wt 
 
Ht 
 
BMI 
 
Y  1  
 
N  2  
 
Y  1  
 
N  2  
 
Y  1  
 
N  2  
 Y  1  
 
N  2  
 
Y  1  
 
N  2  
 
Y  1  
 
N  2  
 
<18.5  1  
 
18.5 -24.9 2  
 
25-29.9  3  
 
30-34.9 4  
 
35-39.9 5  
 
≥40 6  
 
Local   1 Transport 
delay 
2 Financial 
problem  
3 Other  4 
 
 
 
 
 
 Smoking  
 
Alcohol use  
 
Physical activity  
 
Carotid stenosis >70%  
 
 
 
Seizures  
 
 
Hemorrhagic transformation of infarct  
 
 
 
Aspirin  
 
 
 
Clopidogrel   
 
 
LMW heparin 
 
 
Regular heparin  
 
 
 
Y  1  
 
N  2  
 
Y  1  
 
N  2  
 
Y  1  
 
N  2  
 
Y  1  
 
N  2  
 
Y  1  
 
N  2  
 
Before admission 1 After admission 2
Never 3
Before admission 1 After admission 2
Never 3
Before admission   1 After admission   2
Never 3
Before admission 1 After admission 2
Never 3
Y 1 N 2 
Not applicable   9  
 
Not applicable   9  
 
Before & after    4  
 
Before & after    4  
 
Before & after    4  
 
Before & after    4  
 
 Warfarin  
 
 
 
Mannitol 
 
 
 
 
Glycerol  
 
 
 
Statin  
 
 
Ramipril 
 
 
 
 
Infections during hospitalization  
  
Barthel index admission  
Barthel index discharge  
Glasgow outcome score admission  
Glasgow outcome score discharge  
Modified Rankin scale admission  
Modified Rankin scale discharge  
 
Before admission 1 After admission 2
Never 3
Before admission 1 After admission 2
Never 3
Before admission 1 After admission 2
Never 3
Before admission 1 After admission 2
Never 3
Before admission   1 After admission   2
Never 3
Y 1 N 2 
Before & after    4  
 
Before & after    4  
 
Before & after    4  
 
Before & after    
admission  
4  
Before & after    
admission  
4  
 
HbA1C 
During admission Insulin used  
 
Type of Insulin – Regular  
 
Type of Insulin – Mixtard  
 
Type of Insulin – NPH 
 
Type of Insulin – Lantus  
 
Type of Insulin – combination (Mention) 
 
Oral hypoclycemia drugs  
 
Hypoglycemia Episodes 
 
BP at admission – diastolic  
BP at admission – systolic  
Mean arterial pressure  
RBC Count  
Mean Red Cell Volume  
WBC Count  
Platelet count  
Mean Platelet Volume  
 
 
 
 
 
 
 
 
 
 
Y 1 N 2 
Y 1 N 2 
Y 1 N 2 
Y 1 N 2 
Y 1 N 2 
Y 1 N 2 
Y 1 N 2 
Y 1 N 2 
MEAN PLATELET VOLUME IN STROKE –  
CONTROL STUDY  
 
Sl . No.  
Hospital No.      Lab No.  
Name :  Age : 
Gender :   
Weight :    Height :    BMI: 
Hypertension :  
Diabetes: 
Total Cholesterol : 
 
HDL : 
 
LDL : 
 
Triglyceride: 
 
Total Cholesterol : HDL ratio : 
 
Recent Myocardial infarction :  
 
Valvular Heart Disease : 
 
Atrial Fibrillation : 
 
Smoking : 
 
Alcohol Use :  
 
Physical Activity :  
 
Previous History of: 
Drug Intake: 
 
M 1  F 2  
Y 1 N 2 
Y 1 N 2 
Y 1 N 2 
Y 1 N 2 
Y 1 N 2 
Y 1 N 2 
Y 1 N 2 
Y 1 N 2 
RBC Count : 
 
MCV : 
 
WBC Count :  
 
Platelet Count : 
 
Mean Platelet Volume :  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GLASGOW OUTCOME SCORE 
 
 Description  
5 Good recovery : resumption of normal life despite minor deficits  
4 Moderate disability (disabled but independent) : travel by public 
transportation; can work in sheltered setting   
3 Severe disability (conscious but disabled): dependent for daily 
living. 
2 Persistent vegetative state: unresponsive and speechless. After 2-3 
weeks may open eyes and have sleep – wake cycles. 
1 Death  
 
MODIFIED RANKIN SCALE 
 
 Description 
0 No symptoms at all 
1 No significant disability despite symptoms: able to carry out all 
usual duties and activities.  
2 Slight disability: Unable to carry out all previous activities but 
able to look after own affairs without assistance. 
3 Moderate disability : requiring some help but able to walk without 
assistance  
4 Moderate disability: unable to walk without assistance and unable 
to attend to own bodily needs without assistance. 
5 Severe disability : bedridden, incontinent and requiring constant 
nursing care   
6 Death  
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i
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i
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1 34 1 97 174 32.1 2 2 151 38 103 64 3.9 2 2 2 2 2 1 2 5.5 83 9400 2.4 8.6
2 50 1 74 166 26.9 2 2 196 48 110 92 4.1 2 2 2 2 2 1 2 4.8 84 8300 2.7 7.4
3 47 1 64 164 23.8 2 2 179 34 128 91 5.2 2 2 2 2 2 1 2 5 87 9300 3.1 7.3
4 67 1 71 170 24.5 2 2 157 32 111 73 4.9 2 2 2 2 2 1 2 5 85 9300 1.9 8.6
5 58 2 46 156 18.9 2 2 146 53 70 78 2.8 2 2 2 2 2 1 2 4.4 81 5700 2.8 8.8
6 39 2 56 160 21.8 2 2 141 42 72 116 3.3 2 2 2 2 2 1 2 3.9 90 6800 2.8 7
7 45 1 57 168 20.2 2 2 197 45 128 100 4.3 2 2 2 2 2 1 2 4.8 88 8300 2.9 7.2
8 40 2 58 160 22.7 2 2 201 45 135 96 4.5 2 2 2 2 2 1 2 4.8 85 8300 2.4 7.4
9 54 1 83 168 29.4 2 2 170 32 120 70 5.4 2 2 2 2 2 1 2 5.8 81 6300 1.6 8.7
10 50 2 73 165 26.8 2 2 152 51 84 70 3 2 2 2 2 2 1 2 4.2 83 5300 2.5 8.2
11 47 1 54 160 21 2 2 179 37 120 105 4.5 2 2 2 2 2 1 2 5.4 84 5000 2.4 7.4
12 49 1 53 170 18.3 2 2 103 37 54 76 3.3 2 2 2 2 2 1 2 3.8 53 7800 5.5 7.9
13 26 1 68 170 23.5 2 2 169 45 114 72 3.7 2 2 2 2 2 1 2 5.5 83 7900 2.1 8.1
14 45 1 68 162 26 2 2 177 52 105 87 3.4 2 2 2 2 2 1 2 4.6 89 5200 2.1 7.7
15 33 2 76 158 30.5 2 2 199 34 136 187 5.9 2 2 2 2 2 1 2 4.2 87 9000 3 7.6
16 27 1 62 165 22.8 2 2 121 38 64 82 3.2 2 2 2 2 2 1 2 5 79 6500 2.2 7.9
17 33 1 96 180 29.6 2 2 121 36 64 123 3.5 2 2 2 2 2 1 2 5 87 6400 3.2 8.1
18 31 1 74 174 24.5 2 2 171 40 113 115 4.3 2 2 2 2 2 1 2 5.4 84 6900 2.4 7.4
19 49 2 72 162 27.4 2 2 156 35 101 108 4.5 2 2 2 2 2 1 2 4.3 57 7400 3 8.2
20 26 1 72 176 23.3 2 2 143 34 96 75 4.2 2 2 2 2 2 1 2 5.7 84 6700 3 7.7
21 25 1 59 178 18.7 2 2 137 29 95 101 4.7 2 2 2 2 2 1 2 5.1 82 5800 3.1 7.9
22 53 2 72 164 26.8 2 2 182 87 104 76 3.2 2 2 2 2 2 1 2 3.9 90 4800 2.6 8.3
23 30 1 50 174 16.6 2 2 133 34 80 60 3.9 2 2 2 2 2 1 2 5.2 88 5600 2.8 6.9
24 32 2 67 158 26.9 2 2 182 39 122 88 4.6 2 2 2 2 2 1 2 3.5 90 7000 3.3 8.1
25 36 1 65 168 23 2 2 179 35 120 94 5.1 2 2 2 2 2 1 2 4.7 83 4400 2.2 7.8
MASTER CHART - MEAN PLATELET VOLUME IN STROKE - CONTROL STUDY
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26 26 1 62 166 22.5 2 2 163 34 113 172 4.8 2 2 2 2 2 1 2 5 89 6300 2.8 7
27 21 1 53 172 17.9 2 2 153 40 97 70 3.9 2 2 2 2 2 1 2 4.6 91 5700 3.2 6.9
28 31 1 65 174 21.5 2 2 163 38 103 79 4.3 2 2 2 2 2 1 2 5.2 81 7300 2.3 8.1
29 31 2 51 164 19 2 2 150 37 103 70 4 2 2 2 2 2 1 2 4.5 88 5400 2.7 7.7
30 36 1 76 176 24.6 2 2 140 36 86 61 3.8 2 2 2 2 2 1 2 4.8 85 7100 3.7 7.4
31 58 1 75 170 26 2 2 174 38 107 117 4.6 2 2 2 2 2 1 2 4.9 76 8400 3.3 7.9
32 56 1 74 176 24 2 2 156 37 104 71 4.2 2 2 2 2 2 1 2 4.8 87 6300 2.8 7
33 30 2 59 158 23.6 2 2 140 45 83 61 3.1 2 2 2 2 2 1 2 4.2 66 5800 3.3 7
34 34 2 75 156 30 2 2 194 52 127 84 3.7 2 2 2 2 2 1 2 5 77 9000 3.8 7.7
35 33 1 87 166 31.6 2 2 158 38 112 78 4.1 2 2 2 2 2 1 2 5.2 88 7700 3.1 7.6
36 25 2 75 175 24.6 2 2 182 54 113 100 3.4 2 2 2 2 2 1 2 5 88 6600 3 7.2
37 44 2 70 172 23.7 2 2 154 50 93 82 3.1 2 2 2 2 2 1 2 5.5 84 8400 2.5 7.9
38 36 2 65 152 28.1 2 2 122 30 75 93 4.1 2 2 2 2 2 1 2 4.1 83 7700 3.6 6.4
39 51 1 63 162 24 2 2 184 61 95 72 3 2 2 2 2 2 1 2 4.7 82 9100 3.9 7.6
40 37 2 85 160 33.2 2 2 171 34 121 60 5 2 2 2 2 2 1 2 4.5 75 9300 3.6 7.9
41 40 2 59 154 24.8 2 2 178 38 113 95 4.6 2 2 2 2 2 1 2 4.3 86 6800 2.4 8.1
42 38 2 65 154 27.4 2 2 152 27 96 131 5.5 2 2 2 2 2 1 2 4.5 82 6100 3.1 7.7
43 41 1 58 165 21.3 2 2 114 30 73 101 3.8 2 2 2 2 2 1 2 6 76 9600 3 7.4
44 50 1 64 164 23.8 2 2 140 35 90 70 4 2 2 2 2 2 1 2 4.9 92 7000 2.2 7.2
45 42 2 54 158 21.6 2 2 203 43 136 156 4.7 2 2 2 2 2 1 2 4.6 83 9300 2.9 6.9
46 55 1 54 160 21 2 2 184 39 118 163 4.7 2 2 2 2 2 1 2 5 85 9800 3.3 7.2
47 29 1 72 187 20 2 2 184 46 114 98 4 2 2 2 2 2 1 2 4.6 86 5500 2.3 7.7
48 45 2 58 156 23.8 2 2 221 46 141 94 4.8 2 2 2 2 2 1 2 4.3 87 7700 3.8 6.8
49 32 2 54 156 22.2 2 2 158 40 106 72 4 2 2 2 2 2 1 2 4.3 83 7500 2.9 7.3
50 54 1 65 174 21.5 2 2 139 30 93 114 4.6 2 2 2 2 2 1 2 5.3 84 8600 2.5 7
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1 53 1 1 5 9 2 2 30 2220 1 130 2520 3120 1 24 1 24 160 46 92 330 3.5 2 2 2 65 174 21.5 2 1 1 1 2 2 2 2 3
2 57 1 1 1 9 1 2 10 210 1 100 220 400 2 - 1 300 158 30 112 51 5.2 2 2 2 59 160 23.5 2 2 1 2 2 2 3 2 2
3 51 1 1 5 9 3 1 15 1080 1 60 1200 1455 1 144 2 - 121 34 72 54 3.6 2 2 2 - - - 1 1 1 2 2 2 4 4 3
4 57 1 1 4 9 1 1 90 180 1 18 120 150 1 180 1 180 169 33 113 110 5.1 1 2 2 55 161 21.2 2 2 1 3 2 2 2 2 3
5 58 1 2 9 1 1 2 15 160 2 100 150 - 1 36 1 120 213 34 130 265 6.2 2 2 2 - - - 1 1 1 9 2 9 3 3 3
6 52 1 1 1 9 2 2 90 360 1 20 380 500 2 - 2 - 196 47 128 110 4.2 2 2 2 - - - 1 1 1 2 2 2 2 3 2
7 88 2 1 1 9 1 2 360 540 1 30 570 750 2 - 2 - 159 38 98 101 4.2 2 2 2 - - - 2 2 1 3 2 2 3 2 3
8 46 1 1 1 9 2 2 90 1200 1 150 180 210 2 - 2 - 246 36 190 283 6.8 2 2 2 - - - 2 1 1 2 2 2 3 2 3
9 40 1 2 9 1 1 2 30 1440 1 5 60 - 2 - 2 - 173 35 118 169 4.9 2 2 2 - - - 2 2 1 9 2 9 3 3 3
10 43 1 1 5 9 2 2 30 30 2 10 45 120 1 - 2 - 204 32 151 139 6.3 2 2 2 - - - 1 1 1 2 2 2 2 3 3
11 39 1 1 1 9 2 2 30 1440 1 2 120 180 2 - 2 - 151 51 78 73 3 2 2 2 80 160 31.25 2 2 1 2 2 2 2 3 3
12 58 1 1 1 9 1 2 30 720 3 140 750 775 2 - 2 - 248 36 189 130 6.8 2 2 2 - - - 2 1 1 3 2 2 2 3 3
13 65 1 1 1 9 2 2 30 480 1 150 510 570 1 120 2 - 193 40 110 79 4.8 2 2 2 - - - 2 2 1 3 2 2 3 2 3
14 41 2 1 1 9 1 2 30 2880 1 3 60 90 1 36 1 36 156 38 84 108 4.1 2 2 2 - - - 2 2 2 2 2 2 4 3 3
15 35 1 2 9 3 1 2 60 1440 1 100 180 - 2 - 2 - 163 40 110 88 4 2 2 2 65 176 21 1 1 1 9 2 9 3 3 3
16 70 2 1 1 9 2 2 30 30 2 10 40 180 1 18 1 24 208 38 156 133 5.4 2 2 2 - - - 2 2 2 2 2 1 2 2 2
17 57 1 1 4 9 2 2 30 2880 1 15 75 120 1 120 2 - 179 39 111 118 5.1 2 2 2 82 170 28.3 2 2 1 2 2 2 2 3 3
18 51 1 1 1 9 2 2 15 2880 1 150 45 60 1 120 2 - 348 48 244 193 7.3 2 2 2 79 170 27.3 1 1 1 3 2 2 4 3 3
19 60 1 1 1 9 2 1 60 1440 1 80 120 180 1 120 2 - 133 31 78 132 4.3 2 2 2 - - - 2 2 1 1 1 2 4 4 1
20 45 1 1 1 9 1 2 360 610 1 100 390 650 1 24 2 - 199 41 136 123 4.8 2 2 2 56 160 21.8 2 2 1 2 2 2 2 2 3
21 53 1 1 1 9 2 2 60 2880 1 100 75 95 1 6 2 - 100 28 49 172 3.6 1 2 2 65 162 24.8 1 2 1 2 2 2 4 4 1
22 64 1 1 4 9 3 2 60 60 2 25 75 90 2 - 2 - 201 43 129 93 4.7 2 2 2 - - - 2 2 1 3 2 2 3 2 2
23 70 2 1 4 9 3 1 15 900 1 80 240 960 2 - 2 - 172 60 85 46 2.9 2 2 2 - - - 2 2 1 2 2 2 2 3 2
24 44 2 1 9 9 2 2 30 240 1 140 280 - 2 - 2 - 97 25 65 91 3.7 2 2 2 40 150 17.1 2 2 1 9 2 1 3 3 2
25 68 1 2 9 3 2 1 30 180 1 92 210 - 1 36 2 - 229 62 135 157 3.7 2 2 2 65 162 24.8 2 2 1 9 2 1 1 1 3
26 65 1 1 1 9 2 2 2880 2880 2 200 2910 2940 2 - 2 - 222 35 168 139 6.4 2 2 2 50 155 20.8 2 2 1 2 2 2 2 2 2
MASTER CHART - MEAN PLATELET VOLUME IN STROKE - CASE STUDY
27 68 1 1 1 9 2 2 60 80 1 10 90 110 2 - 2 - 140 32 82 166 4.4 2 2 2 57 155 23.75 2 2 1 2 2 2 4 1 3
28 52 1 1 4 9 3 2 30 2880 1 10 2910 2950 2 - 1 12 184 34 132 78 5.4 2 2 2 64 170 22.1 2 1 1 2 2 2 3 2 3
29 35 2 1 1 9 1 2 60 300 1 140 90 330 2 - 1 6 196 32 126 76 6.1 2 2 2 75 159 29.76 2 2 1 2 2 2 3 2 3
30 56 1 2 9 1 2 2 60 720 1 80 750 - 1 24 1 84 222 35 168 150 6.3 2 2 2 - - - 1 1 1 9 2 9 3 3 3
31 55 2 1 4 9 3 2 120 4320 1 90 500 550 2 - 2 - 135 35 86 78 3.9 2 2 2 55 160 21.48 2 2 1 3 2 2 2 3 3
32 60 2 1 1 9 2 2 120 180 1 80 200 220 1 1 2 - 169 34 109 114 4.9 2 2 2 57 155 23.75 2 2 1 3 2 2 2 2 3
33 60 1 2 9 3 2 2 30 250 1 40 240 - 2 - 2 - 230 38 110 78 6.1 2 2 2 - - - 1 2 1 9 2 9 3 3 3
34 76 1 1 2 9 2 2 30 720 1 15 750 780 1 3 1 3 180 40 127 105 4.5 1 2 2 - - - 2 2 1 2 2 2 2 2 3
35 70 1 1 1 9 1 2 30 90 1 5 110 140 2 - 1 60 140 42 130 110 3.3 2 1 2 - - - 1 1 1 3 2 2 3 2 3
36 48 1 1 1 9 2 2 60 180 1 100 400 430 1 1 1 1 151 44 87 70 3.4 2 2 2 52 160 20.3 2 2 1 2 2 2 1 4 3
37 68 1 2 9 6 2 2 30 120 1 70 150 - 1 72 2 - 195 40 104 202 4.8 2 2 2 - - - 1 1 1 9 2 9 3 3 3
38 49 1 1 1 9 2 2 30 2160 1 90 240 280 2 - 2 - 155 32 102 130 4.8 2 2 2 - - - 2 2 1 3 2 2 3 2 1
39 71 1 2 9 1 2 1 30 270 1 180 300 - 1 48 1 240 107 40 110 105 2.6 2 2 2 - - - 2 2 1 9 2 1 1 3 3
40 60 1 1 5 9 2 1 30 2880 1 10 120 180 1 120 1 120 86 32 40 114 2.7 2 2 2 - - - 2 1 1 2 2 2 1 4 3
41 47 1 1 2 9 2 2 60 90 1 20 120 180 1 12 2 - 132 31 84 94 4.3 2 2 2 - - - 2 2 1 2 2 2 2 3 3
42 54 1 1 1 9 1 2 45 45 2 15 90 120 1 48 2 - 272 42 188 169 6.4 2 2 2 72 170 24.9 1 1 1 2 2 2 3 2 3
43 70 1 1 1 9 2 2 2880 3000 3 45 2940 3020 1 4 1 180 181 30 109 212 6 2 2 2 60 160 23.43 2 2 1 2 2 2 1 2 3
44 51 2 1 1 9 1 2 30 1560 1 10 100 150 2 - 1 72 125 23 80 143 5.6 2 2 2 51 151 22.36 2 2 1 2 2 2 3 2 3
45 30 1 1 1 9 1 2 360 4320 1 15 480 - 2 - 2 - 200 40 100 75 5 2 2 2 40 155 16 1 1 1 3 2 2 3 3 3
46 50 1 1 1 9 1 2 30 2880 1 150 200 250 1 120 1 204 176 40 110 196 4.4 2 2 2 - - - 1 1 1 3 2 2 1 1 3
47 51 1 1 4 9 2 2 45 2880 1 200 240 300 1 60 1 132 134 30 78 113 4.4 2 2 2 56 153 23.93 2 2 1 3 2 2 4 4 3
48 65 1 2 9 1 1 2 35 90 1 30 140 - 1 36 2 - 140 42 90 110 3.3 2 2 2 - - - 2 1 1 9 2 9 3 3 3
49 77 1 1 1 9 2 2 30 60 1 10 75 120 2 - 2 - 115 35 70 51 3.3 2 2 2 65 160 25.39 2 2 1 2 2 2 3 2 3
50 84 1 1 1 9 1 2 45 1440 1 50 1400 1500 2 - 1 120 147 28 96 80 5.2 1 2 2 - - - 1 1 1 2 2 2 2 2 3
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3 3 3 3 2 2 2 40 80 3 4 4 3 14.3 1 1 1 2 2 1 1 2 80 130 96.6 4.1 91 6300 1.5 8.6
3 3 2 3 2 2 2 - 55 3 4 5 4 12 1 1 1 2 2 1 2 2 70 150 96.6 4.4 80 13600 3 6.5
2 3 3 3 2 2 1 - 45 3 4 4 4 - 2 2 2 2 2 2 2 2 90 120 100 4.3 91 10700 2.2 7.7
3 3 3 3 2 2 2 50 75 3 5 4 3 9.2 1 1 1 2 2 1 1 2 100 190 130 4.5 84 13300 2.2 7.4
3 3 4 2 3 2 1 - 50 3 3 4 4 14.7 1 1 2 2 2 2 1 2 110 210 143.3 4.2 83 10000 1.6 7.6
2 2 2 2 2 2 1 - 40 3 3 5 4 - 2 2 2 2 2 2 2 2 90 140 106.6 4.2 100 9100 2.6 7
3 3 3 3 2 2 1 25 40 3 3 4 4 - 2 2 2 2 2 2 2 2 80 160 106.6 3.9 86 8800 2.4 8.1
3 3 3 3 2 2 2 50 50 3 3 3 3 - 2 2 2 2 2 2 2 2 110 140 120 4.8 92 9000 2.3 8.4
3 3 4 4 3 2 2 50 65 3 4 4 4 - 2 2 2 2 2 2 2 2 130 190 150 5.8 82 20700 2.5 9.2
3 3 3 3 2 2 2 85 100 4 5 5 2 - 2 2 2 2 2 2 2 2 110 220 143.3 4.6 93 5700 1.8 7.3
3 3 2 2 2 2 1 - 100 3 5 5 0 - 2 2 2 2 2 2 2 2 90 140 106.6 4.7 83 14400 2 7.6
3 3 2 2 2 2 2 - - 3 3 4 4 - 2 2 2 2 2 2 2 2 110 150 123.3 4.5 91 7500 1.4 7.2
3 3 3 3 2 2 2 - - 3 3 4 4 - 2 2 2 2 2 2 2 2 80 110 90 4.1 83 14800 3.4 7.9
3 3 3 3 2 2 2 - 50 3 3 4 4 10 1 1 1 2 2 1 1 2 100 150 116.6 3 87 8900 1.8 7.7
3 3 3 3 3 2 1 5 85 3 5 5 2 - 2 2 2 2 2 2 2 2 100 170 123 5.2 88 12200 2.3 9.6
3 2 3 3 2 2 1 - 15 3 3 5 4 11 1 1 1 2 2 1 2 2 100 140 113.3 4.5 82 8500 2 7.3
3 3 3 3 2 2 1 25 75 3 5 4 3 - 2 2 2 2 2 2 2 2 110 190 136.6 4.3 86 10800 3.5 7.9
3 3 3 3 4 2 2 70 90 5 5 3 2 - 2 2 2 2 2 2 2 2 110 180 133.3 4.4 86 9900 3.4 7
1 3 3 3 2 2 1 30 30 3 4 4 4 - 2 2 2 2 2 2 2 2 70 110 113.3 4.8 86 6300 1.8 9.2
3 2 3 3 2 2 2 20 75 3 4 5 3 - 2 2 2 2 2 2 2 2 90 150 110 5.5 74 11200 2.1 7
3 3 3 3 4 2 2 25 40 4 5 4 3 - 2 2 2 2 2 2 2 2 90 120 100 4.9 82 16400 3.2 7.3
2 2 3 2 2 2 1 - 20 3 4 5 4 12.6 1 1 1 2 2 1 2 2 100 160 120 4.4 85 7800 1.6 8.4
3 3 3 3 2 3 2 - 60 4 4 5 5 - 2 2 2 2 2 2 2 2 90 150 110 3.8 90 18800 3.4 6.7
3 2 4 3 3 3 1 - 60 2 4 5 3 8 2 2 2 2 2 2 2 2 100 140 113.3 4.6 54 4200 3.1 7.4
3 3 3 3 4 1 2 85 95 4 5 2 1 8.7 2 2 2 2 2 2 2 2 100 170 123 4.3 85 8500 2.3 6.9
3 2 3 3 2 2 2 45 65 3 4 5 4 - 2 2 2 2 2 2 2 2 100 150 116.6 4.4 83 6800 2.97 7.2
3 3 3 3 2 2 2 40 85 4 5 4 3 - 2 2 2 2 2 2 2 2 120 220 153.3 5 83 6800 2.73 6.8
3 3 3 3 2 3 2 85 95 4 5 2 1 5.7 1 1 2 2 2 2 1 2 110 200 140 4.9 84 9000 3.1 8.1
3 3 3 3 2 2 2 40 85 4 5 4 3 7.5 2 2 2 2 2 2 1 2 100 180 126.6 4.8 71 12500 2.7 8.3
3 3 2 2 2 2 1 - 10 3 3 4 4 - 1 1 1 2 2 1 2 2 100 160 120 4.5 79 9000 3.7 8.6
3 3 2 3 2 2 2 - 80 3 4 5 2 - 2 2 2 2 2 2 2 2 80 130 146.6 4.9 83 21700 3 8.1
3 3 3 3 2 2 2 45 60 4 4 4 4 - 2 2 2 2 2 2 2 2 90 140 106.4 3.8 92 9100 3.4 6.9
3 3 2 3 3 2 1 - 40 3 3 5 4 - 2 2 2 2 2 2 2 2 120 230 156.6 3.2 73 7100 2 9.6
2 3 3 3 2 2 2 50 70 3 4 4 3 - 1 1 2 2 2 2 1 2 90 150 110 5.2 84 8400 2.2 8.3
2 2 3 3 2 3 1 45 60 4 4 4 4 - 1 1 2 2 2 2 2 1 70 100 80 4.7 77 8200 3.1 8.2
3 3 3 3 4 2 2 90 95 4 4 1 1 4.5 2 2 2 2 2 2 2 2 110 150 130 5.1 88 7900 2.26 8.1
3 3 2 3 3 3 1 - 45 2 4 5 3 - 2 2 2 2 2 2 2 2 96 150 106 5.2 86 14500 2.5 7.9
3 3 4 4 2 2 1 - 20 2 3 3 4 - 2 2 2 2 2 2 2 2 100 150 116.6 5.1 57 16600 3.7 8.1
3 3 2 3 4 4 2 - 10 2 2 4 4 - 2 2 2 2 2 2 2 2 80 200 120 4.3 89 12900 2.1 6.5
1 1 1 1 4 2 2 5 40 3 3 5 4 6.6 1 1 2 2 2 2 2 1 80 150 103.3 4.3 74 8000 2.4 8.3
3 3 3 3 2 2 1 15 30 3 3 4 4 - 2 2 2 2 2 2 2 2 90 190 123.3 4.7 85 10900 2.3 7.8
3 3 3 3 2 2 2 35 95 4 5 4 1 - 2 2 2 2 2 2 2 2 160 260 193.3 5.7 87 6800 2.5 9
3 3 3 3 4 2 2 40 10 4 3 4 5 5.8 1 1 2 2 2 2 2 2 120 160 133.3 5.5 81 12200 2.6 7.2
3 3 3 3 2 2 2 85 95 5 4 2 1 7.4 1 1 2 2 2 2 1 2 80 130 96.6 3.6 86 7800 2.7 6.8
3 3 2 3 3 3 1 10 20 3 3 4 4 - 2 2 2 2 2 2 2 2 80 140 100 3.4 98 6700 1.6 8.3
3 3 4 3 1 2 2 - 10 2 2 5 5 - 1 1 2 2 2 2 2 2 70 90 77 6.5 82 19300 2.5 8.8
3 3 3 3 2 2 2 95 100 4 5 3 2 - 2 2 2 2 2 2 2 2 90 180 120 3.6 86 8900 2.9 7
3 3 2 2 3 3 2 - 5 2 2 5 5 - 2 2 2 2 2 2 2 2 110 230 150 5.3 82 30100 2.8 8.4
3 3 3 3 2 2 2 85 85 4 4 2 2 - 2 2 2 2 2 2 2 2 90 140 106 4.9 88 7400 2.5 7.3
2 3 3 3 2 2 1 - 30 4 4 4 4 6.3 2 2 2 2 2 2 1 2 100 170 123 3.8 91 9500 2.2 8.2
 
